<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="3132b965-d332-43a4-a156-d29b7d0fab8d"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use SIVEXTRO<sup>®</sup> safely and effectively. See full prescribing information for SIVEXTRO. <br/>
      <br/>SIVEXTRO (tedizolid phosphate) for injection, for intravenous use  <br/>SIVEXTRO (tedizolid phosphate) tablet, for oral use<br/> Initial U.S. Approval:  2014</title>
   <effectiveTime value="20250404"/>
   <setId root="75672079-589f-451a-bdbf-eaebcfcc80a9"/>
   <versionNumber value="31"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="118446553" root="1.3.6.1.4.1.519.1"/>
            <name>Merck Sharp &amp; Dohme LLC</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="579dd2a4-ae1f-4330-a4de-8dc5b0fc96a0"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250404"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="67919-041" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>SIVEXTRO</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tedizolid phosphate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="200" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="O7DRJ6R4DW" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tedizolid phosphate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="97HLQ82NGL" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tedizolid</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>mannitol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="68401960MK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>crospovidone (15 MPA.S AT 5%)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>magnesium stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>titanium dioxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>talc</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ferric oxide yellow</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="67919-041-04" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20140620"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="6" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="67919-041-05" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20140620"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA205435" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20140620"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="14" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">TZD;200</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="67919-040" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>SIVEXTRO</name>
                        <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tedizolid phosphate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="200" unit="mg"/>
                              <denominator value="4" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="O7DRJ6R4DW" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tedizolid phosphate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="97HLQ82NGL" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tedizolid</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="105" unit="mg"/>
                              <denominator value="4" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>mannitol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>sodium hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>hydrochloric acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="4" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43209" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, GLASS"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="67919-040-02" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20140620"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA205436" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20140620"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>white to off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="6fdbc856-7a2b-4632-a963-2dda66bd1907"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250404"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="75%" align="left" valign="top"/>
                           <col width="25%" align="right" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>Indications and Usage (<linkHtml href="#S1.1">1.1</linkHtml>, <linkHtml href="#S1.2">1.2</linkHtml>)</td>
                                 <td>4/2025</td>
                              </tr>
                              <tr>
                                 <td>Dosage and Administration (<linkHtml href="#S2.1">2.1</linkHtml>, <linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S2.3">2.3</linkHtml>, <linkHtml href="#S2.4">2.4</linkHtml>, <linkHtml href="#S2.5">2.5</linkHtml>, <linkHtml href="#S2.6">2.6</linkHtml>, <linkHtml href="#S2.7">2.7</linkHtml>)</td>
                                 <td>4/2025</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="3cbd2a5f-a92f-4eb1-8e39-f9dcc0903755"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20250404"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>SIVEXTRO is an oxazolidinone antibacterial indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible microorganisms in adult and pediatric patients (at least 26 weeks gestational age and weighing at least 1 kg) (<linkHtml href="#S1.1">1.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="underline">Usage to Reduce Development of Drug-Resistant Bacteria</content>
                           <br/>To reduce the development of drug-resistant bacteria and maintain the effectiveness of SIVEXTRO and other antibacterial drugs, SIVEXTRO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S1.1">
                     <id root="3215df36-6795-4c01-b587-3f85590ee86d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1    Acute Bacterial Skin and Skin Structure Infections</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">SIVEXTRO<sup>®</sup> is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following gram-positive microorganisms: <content styleCode="italics">Staphylococcus aureus </content>(including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), <content styleCode="italics">Streptococcus pyogenes</content>, <content styleCode="italics">Streptococcus agalactiae</content>,<content styleCode="italics"> Streptococcus anginosus</content> Group (including <content styleCode="italics">Streptococcus anginosus</content>, <content styleCode="italics">Streptococcus intermedius</content>, and <content styleCode="italics">Streptococcus constellatus</content>), and <content styleCode="italics">Enterococcus faecalis</content>, in adult and pediatric patients (at least 26 weeks gestational age and weighing at least 1 kg).</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.2">
                     <id root="35f3acf7-c61e-4e79-99e5-b5918fcf168d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">1.2 Usage to Reduce Development of Drug-Resistant Bacteria</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">To reduce the development of drug-resistant bacteria and maintain the effectiveness of SIVEXTRO and other antibacterial drugs, SIVEXTRO should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="e39551c5-e462-4f5a-9ab5-be144367da8d"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250404"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Do <content styleCode="bold">not</content> administer SIVEXTRO Tablets to pediatric patients weighing less than 35 kg. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Adult Patients Intravenous and Oral Dosage</content>
                              <content styleCode="bold">:</content> 200 mg administered once daily orally or as an intravenous (IV) infusion over 1 hour for 6 days as specified in Table 1 in the full prescribing information. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Pediatric Patients Intravenous Dosage</content>
                              <content styleCode="bold"> (at least 26 weeks gestational age and weighing at least 1 kg):</content> Weight-based dosing as an intravenous infusion as specified in Table 2 in the full prescribing information. (<linkHtml href="#S2.3">2.3</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Pediatric Patients Oral Dosage</content>
                              <content styleCode="bold"> (weighing greater than or equal to 35 kg):</content> Weight-based dosing as an oral tablet administered once daily as specified in Table 3 in the full prescribing information. (<linkHtml href="#S2.3">2.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="a324aaab-2cf3-4c74-a464-62a580314dbb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">2.1 Important Administration Instructions for Pediatric Patients Weighing Less than 35 kg</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Do <content styleCode="bold">not</content> administer SIVEXTRO Tablets to pediatric patients weighing less than 35 kg <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration 2.3</linkHtml>].</content>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="f50eaa96-ef6b-46a7-a82f-2208cbef5979"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">2.2 Recommended Dosage for Adult Patients</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">The recommended dosage of SIVEXTRO is 200 mg administered once daily for six (6) days either as an oral tablet (with or without food) or as an intravenous (IV) infusion in adult patients.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">The recommended dosage and administration of SIVEXTRO in adult patients are described in <linkHtml href="#t1">Table 1</linkHtml>.</content>
                        </paragraph>
                        <table width="100%" ID="t1">
                           <caption>Table 1: Recommended Dosage of SIVEXTRO for Adult Patients</caption>
                           <colgroup>
                              <col width="24%" align="left" valign="middle"/>
                              <col width="14%" align="center" valign="middle"/>
                              <col width="14%" align="center" valign="middle"/>
                              <col width="14%" align="center" valign="middle"/>
                              <col width="17%" align="center" valign="middle"/>
                              <col width="17%" align="center" valign="middle"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">
                                    <content styleCode="xmChange">Infection</content>
                                 </th>
                                 <th styleCode="Rrule">
                                    <content styleCode="xmChange">Route</content>
                                 </th>
                                 <th styleCode="Rrule">
                                    <content styleCode="xmChange">Dose</content>
                                 </th>
                                 <th styleCode="Rrule">
                                    <content styleCode="xmChange">Frequency</content>
                                 </th>
                                 <th styleCode="Rrule">
                                    <content styleCode="xmChange">Infusion Time</content>
                                 </th>
                                 <th styleCode="Rrule">
                                    <content styleCode="xmChange">Duration of Treatment</content>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="2">Acute Bacterial Skin and Skin <br/>Structure Infections <br/>(ABSSSI)</td>
                                 <td styleCode="Rrule">Intravenous</td>
                                 <td styleCode="Rrule">200 mg</td>
                                 <td styleCode="Rrule">Once daily</td>
                                 <td styleCode="Rrule">1 hour</td>
                                 <td styleCode="Rrule" rowspan="2">6 days</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule">Oral</td>
                                 <td styleCode="Rrule">200 mg</td>
                                 <td styleCode="Rrule">Once daily</td>
                                 <td styleCode="Rrule">Not Applicable</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>No dose adjustment is necessary when changing from intravenous to oral SIVEXTRO.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="55ea9c06-2e22-44e2-acdd-7509b18735dd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">2.3 Recommended Dosage for Pediatric Patients</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="underline">Recommended Dosage of SIVEXTRO for Injection for Pediatric Patients: Intravenous Dosage</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">The recommended intravenous dosage of SIVEXTRO for Injection for pediatric patients (at least 26 weeks gestational age and weighing at least 1 kg) is presented in <linkHtml href="#t2">Table 2</linkHtml>.</content>
                        </paragraph>
                        <table width="100%" ID="t2">
                           <caption>Table 2: Recommended Intravenous Dosage of SIVEXTRO for Injection for Pediatric Patients</caption>
                           <colgroup>
                              <col width="30%" align="center" valign="middle"/>
                              <col width="10%" align="center" valign="middle"/>
                              <col width="20%" align="center" valign="middle"/>
                              <col width="20%" align="center" valign="middle"/>
                              <col width="20%" align="center" valign="middle"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">
                                    <content styleCode="xmChange">Weight Band (kg)</content>
                                 </th>
                                 <th styleCode="Rrule">
                                    <content styleCode="xmChange">Dose</content>
                                 </th>
                                 <th styleCode="Rrule">
                                    <content styleCode="xmChange">Frequency</content>
                                 </th>
                                 <th styleCode="Rrule">
                                    <content styleCode="xmChange">Infusion Time</content>
                                 </th>
                                 <th styleCode="Rrule">
                                    <content styleCode="xmChange">Duration of Treatment</content>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" colspan="5">
                                    <content styleCode="bold">Pediatric Patients Weighing Less than 2 kg</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">1 to less than 2<content styleCode="bold">
                                       <footnote ID="t2f1">Recommended Dosage for 1 kg to less than 2 kg is based on actual body weight.</footnote>
                                    </content>
                                 </td>
                                 <td styleCode="Rrule">3 mg/kg</td>
                                 <td styleCode="Rrule">Twice daily</td>
                                 <td styleCode="Rrule">1 hour</td>
                                 <td styleCode="Rrule">6 days</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" colspan="5">
                                    <content styleCode="bold">Pediatric Patients Weighing at Least 2 kg</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">2 to less than 3</td>
                                 <td styleCode="Rrule">6 mg</td>
                                 <td styleCode="Rrule" rowspan="6">Twice daily</td>
                                 <td styleCode="Rrule" rowspan="6">1 hour</td>
                                 <td styleCode="Rrule" rowspan="6">6 days</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">3 to less than 6</td>
                                 <td styleCode="Rrule">12 mg</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">6 to less than 10</td>
                                 <td styleCode="Rrule">20 mg</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">10 to less than 14</td>
                                 <td styleCode="Rrule">30 mg</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">14 to less than 20</td>
                                 <td styleCode="Rrule">40 mg</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">20 to less than 35</td>
                                 <td styleCode="Rrule">60 mg</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" colspan="5">
                                    <content styleCode="bold">Pediatric Patients Weighing at Least 35 kg</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Greater than or equal to 35</td>
                                 <td styleCode="Rrule">200 mg</td>
                                 <td styleCode="Rrule">Once daily</td>
                                 <td styleCode="Rrule">1 hour</td>
                                 <td styleCode="Rrule">6 days</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="underline">Recommended Dosage of SIVEXTRO Tablets for Pediatric Patients: Oral Dosage</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">The recommended oral dosage of SIVEXTRO Tablets for pediatric patients is presented in <linkHtml href="#t3">Table 3</linkHtml>. SIVEXTRO Tablets can be administered with or without food. Do <content styleCode="bold">not</content> administer SIVEXTRO Tablets to pediatric patients weighing less than 35 kg.</content>
                        </paragraph>
                        <table width="100%" ID="t3">
                           <caption>Table 3: Recommended Oral Tablet Dosage of SIVEXTRO for Pediatric Patients</caption>
                           <colgroup>
                              <col width="40%" align="center" valign="middle"/>
                              <col width="18%" align="center" valign="middle"/>
                              <col width="21%" align="center" valign="middle"/>
                              <col width="21%" align="center" valign="middle"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">
                                    <content styleCode="xmChange">Weight Band (kg)</content>
                                 </th>
                                 <th styleCode="Rrule">
                                    <content styleCode="xmChange">Dose</content>
                                 </th>
                                 <th styleCode="Rrule">
                                    <content styleCode="xmChange">Frequency</content>
                                 </th>
                                 <th styleCode="Rrule">
                                    <content styleCode="xmChange">Duration of Treatment</content>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Greater than or equal to 35</td>
                                 <td styleCode="Rrule">200 mg</td>
                                 <td styleCode="Rrule">Once daily</td>
                                 <td styleCode="Rrule">6 days</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="xmChange">No dose adjustment is necessary when changing from intravenous to oral SIVEXTRO.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="9504e81a-ada1-4c45-abc5-2ad1a569a367"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">2.4 Recommendations Regarding Missed Doses(s)</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="underline">For Once Daily Oral Dosing of SIVEXTRO Tablets</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">If patients miss a dose, administer the dose as soon as possible anytime up to 8 hours prior to their next scheduled dose. If less than 8 hours remain before the next dose, instruct the patients to wait until their next scheduled dose.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.5">
                     <id root="d3c661aa-df03-408c-b512-e0fb42047dc9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">2.5 Preparation and Administration of Intravenous Solution</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">SIVEXTRO is supplied as a sterile, lyophilized powder for injection in single-dose vials of 200 mg. Each 200 mg vial must be reconstituted with Sterile Water for Injection and subsequently diluted with 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP.</content>
                        </paragraph>
                        <paragraph>SIVEXTRO vials contain no antimicrobial preservatives and are intended for single dose only. Discard any unused portion.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                     <component>
                        <section>
                           <id root="d5e10825-3aac-4c81-98c1-b58478d74bf9"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="xmChange">
                                    <content styleCode="underline">Preparation of SIVEXTRO for Injection</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">The contents of the vial should be reconstituted using aseptic technique as follows:</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">Note: To minimize foaming, AVOID vigorous agitation or shaking of the vial during or after reconstitution.</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">
                                    <content styleCode="bold">For Adults and Pediatric Patients Weighing at Least 35 kg:</content>
                                 </content>
                              </paragraph>
                              <list listType="ordered">
                                 <item>
                                    <content styleCode="xmChange">Reconstitute the SIVEXTRO vial with 4 mL of Sterile Water for Injection to provide a concentration of 50 mg/mL in each vial.</content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">Gently swirl the contents and let the vial stand until the cake has completely dissolved and any foam disperses.<br/>
                                       <br/>Inspect the vial to ensure the solution contains no particulate matter and no cake or powder remains attached to the sides of the vial. If necessary, invert the vial to dissolve any remaining powder and swirl gently to prevent foaming. The reconstituted solution is clear and colorless to pale-yellow in color; the total time from reconstitution to the end of administration should not exceed 24 hours at either room temperature or under refrigeration at 2°C to 8°C (36°F to 46°F).<br/>
                                       <br/>Tilt the upright vial and insert a syringe with appropriately sized needle into the bottom corner of the vial and remove 4 mL of the reconstituted solution for the 200 mg dose. Do not invert the vial during extraction.</content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">The reconstituted solution must be further diluted in 250 mL of 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP. Slowly inject the required volume of reconstituted solution as determined in Step 2 into a 250 mL bag of 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP. Invert the bag gently to mix. Do NOT shake the bag as this may cause foaming.</content>
                                 </item>
                              </list>
                              <paragraph>
                                 <content styleCode="xmChange">
                                    <content styleCode="bold">For Pediatric Patients Weighing Less than 35 kg:</content>
                                 </content>
                              </paragraph>
                              <list listType="ordered">
                                 <item>
                                    <content styleCode="xmChange">Reconstitute the SIVEXTRO vial with 4 mL of Sterile Water for Injection to provide a concentration of 50 mg/mL in each vial.</content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">Gently swirl the contents and let the vial stand until the cake has completely dissolved and any foam disperses.</content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">Inspect the vial to ensure the solution contains no particulate matter and no cake or powder remains attached to the sides of the vial. If necessary, invert the vial to dissolve any remaining powder and swirl gently to prevent foaming. The reconstituted solution is clear and colorless to pale-yellow in color; the total time from reconstitution to the end of administration should not exceed 24 hours at either room temperature or under refrigeration at 2°C to 8°C (36°F to 46°F).<br/>
                                       <br/>Prepare a stock solution (100 mL of 0.8 mg/mL tedizolid phosphate): Tilt the upright vial and insert a syringe with appropriately sized needle into the bottom corner of the vial and remove 1.6 mL of the reconstituted solution and add it to an infusion bag containing 98.4 mL of 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP. Do <content styleCode="bold">not</content> invert the vial during extraction.</content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">Prepare the required volume of stock solution for infusion: Refer to <linkHtml href="#t4">Table 4</linkHtml> to convert the dose in mg to the appropriate volume of stock solution to be administered. Transfer this volume of stock solution to an adequately sized infusion bag or infusion syringe. It may be necessary to round to the nearest graduation mark of an appropriately sized syringe for smaller volumes. The total time from reconstitution to the end of administration should not exceed 24 hours at either room temperature or under refrigeration at 2°C to 8°C (36°F to 46°F).</content>
                                 </item>
                              </list>
                              <table width="100%" ID="t4">
                                 <caption>Table 4: Preparation of SIVEXTRO for Injection for Pediatric Patients Weighing 1 kg to Less than 35 kg from the 100 mL Stock Solution of 0.8 mg/mL Tedizolid Phosphate</caption>
                                 <colgroup>
                                    <col width="30%" align="center" valign="middle"/>
                                    <col width="40%" align="center" valign="middle"/>
                                    <col width="30%" align="center" valign="middle"/>
                                 </colgroup>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">
                                          <content styleCode="xmChange">Body Weight (kg)</content>
                                       </th>
                                       <th styleCode="Rrule">
                                          <content styleCode="xmChange">Amount of SIVEXTRO per dose<br/>
                                             <br/>(given twice daily)</content>
                                       </th>
                                       <th styleCode="Rrule">
                                          <content styleCode="xmChange">Volume of stock solution (0.8 mg/mL) to be transferred to an adequately sized infusion bag or infusion syringe</content>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" align="center" colspan="3">
                                          <content styleCode="bold">Pediatric Patients Weighing Less than 2 kg</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">1 to less than 2</td>
                                       <td styleCode="Rrule">3 mg/kg</td>
                                       <td styleCode="Rrule">Volume (mL) = Weight (kg) x 3.75 mL/kg</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" align="center" colspan="3">
                                          <content styleCode="bold">Pediatric Patients Weighing at Least 2 kg</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">2 to less than 3</td>
                                       <td styleCode="Rrule">6 mg</td>
                                       <td styleCode="Rrule">7.5 mL</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">3 to less than 6</td>
                                       <td styleCode="Rrule">12 mg</td>
                                       <td styleCode="Rrule">15 mL</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">6 to less than 10</td>
                                       <td styleCode="Rrule">20 mg</td>
                                       <td styleCode="Rrule">25 mL</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">10 to less than 14</td>
                                       <td styleCode="Rrule">30 mg</td>
                                       <td styleCode="Rrule">37.5 mL</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">14 to less than 20</td>
                                       <td styleCode="Rrule">40 mg</td>
                                       <td styleCode="Rrule">50 mL</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">20 to less than 35</td>
                                       <td styleCode="Rrule">60 mg</td>
                                       <td styleCode="Rrule">75 mL</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="91e989a1-542b-4f41-aa5d-6de726b98cba"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="xmChange">
                                    <content styleCode="underline">Administration of SIVEXTRO for Injection</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">Administer SIVEXTRO for Injection as an intravenous infusion only.</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">Do not administer as an intravenous push or bolus. Do not mix SIVEXTRO for Injection with other drugs when administering. It is not intended for intra-arterial, intramuscular, intrathecal, intraperitoneal, or subcutaneous administration.</content>
                              </paragraph>
                              <paragraph>The intravenous bag containing the reconstituted and diluted intravenous solution should be inspected visually for particulate matter prior to administration.  Discard if visible particles are observed.  The resulting solution is clear and colorless to pale-yellow in color.</paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">After reconstitution and dilution, SIVEXTRO for Injection is to be administered via intravenous infusion using a total time of 1 hour.</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">The total time from reconstitution to the end of administration of SIVEXTRO for Injection should not exceed 24 hours at either room temperature or under refrigeration at 2°C to 8°C (36°F to 46°F).</content>
                              </paragraph>
                              <paragraph>Discard unused portion.</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.6">
                     <id root="5ee85a69-809b-46a1-a832-d7cf9d6b3c83"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Compatible Intravenous Solutions</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">SIVEXTRO is compatible with 0.9% Sodium Chloride Injection, USP and 5% Dextrose Injection, USP.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Limited data are available on the compatibility of SIVEXTRO for Injection with other intravenous substances, additives or other medications and they should not be added to SIVEXTRO single-dose vials or infused simultaneously. If the same intravenous line is used for sequential infusion of several different drugs, the line should be flushed before and after infusion of SIVEXTRO with 0.9% Sodium Chloride Injection, USP.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.7">
                     <id root="d8a75e55-74fb-45d9-a513-08d20daad62c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.7 Incompatibilities</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">SIVEXTRO for Injection is incompatible with any solution containing divalent cations (e.g., Ca<sup>2+</sup>, Mg<sup>2+</sup>), including Lactated Ringer’s Injection and Hartmann’s Solution.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="9bf1c2af-5cd5-4865-b06b-efac61c33a0b"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>SIVEXTRO 200 mg tablet is a yellow film-coated oval tablet; each tablet is debossed with "TZD" on one side and "200" on the other side.</paragraph>
                  <paragraph>SIVEXTRO for Injection is a sterile, white to off-white lyophilized powder for injection in single-dose vials of 200 mg. Each 200 mg vial must be reconstituted with Sterile Water for Injection and subsequently diluted with 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP.</paragraph>
               </text>
               <effectiveTime value="20250404"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>For injection: 200 mg, sterile, lyophilized powder in single-dose vial for reconstitution for intravenous infusion. (<linkHtml href="#S3">3</linkHtml>)</item>
                           <item> Tablet: 200 mg (<linkHtml href="#S3">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="bfdbbda4-7146-4de2-82b2-535395da857f"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20250404"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="f396aa1b-227b-44d3-b66c-39b63302d46f"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250404"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Patients with neutropenia: The safety and efficacy of SIVEXTRO in patients with neutropenia (neutrophil counts &lt;1000 cells/mm<sup>3</sup>) have not been adequately evaluated. In an animal model of infection, the antibacterial activity of SIVEXTRO was reduced in the absence of granulocytes. Consider alternative therapies in neutropenic patients. (<linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Clostridioides difficile</content>-associated diarrhea: Evaluate if diarrhea occurs. (<linkHtml href="#S5.2">5.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="50d03b5b-20e8-48fe-ac03-8af97c2a5c78"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1    Patients with Neutropenia</title>
                     <text>
                        <paragraph>The safety and efficacy of SIVEXTRO in patients with neutropenia (neutrophil counts &lt;1000 cells/mm<sup>3</sup>) have not been adequately evaluated.  In an animal model of infection, the antibacterial activity of SIVEXTRO was reduced in the absence of granulocytes <content styleCode="italics">[see <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]</content>. Alternative therapies should be considered when treating patients with neutropenia and ABSSSI.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="adac1e4f-34f5-45c0-b3db-eaff67528f70"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2    <content styleCode="italics">Clostridioides difficile</content>-Associated Diarrhea</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Clostridioides difficile</content>-associated diarrhea (CDAD) has been reported for nearly all systemic antibacterial agents including SIVEXTRO, with severity ranging from mild diarrhea to fatal colitis.  Treatment with antibacterial agents can alter the normal flora of the colon and may permit overgrowth of <content styleCode="italics">C. difficile</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">C. difficile</content> produces toxins A and B which contribute to the development of CDAD.  Hypertoxin producing strains of <content styleCode="italics">C. difficile</content> cause increased morbidity and mortality, as these infections can be refractory to antibacterial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary because CDAD has been reported to occur more than two months after the administration of antibacterial agents. </paragraph>
                        <paragraph>If CDAD is suspected or confirmed, antibacterial use not directed against <content styleCode="italics">C. difficile</content> should be discontinued, if possible.  Appropriate measures such as fluid and electrolyte management, protein supplementation, antibacterial treatment of <content styleCode="italics">C. difficile</content>, and surgical evaluation should be instituted as clinically indicated.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="f018bb09-ef17-4869-bbc2-0be621dddbf3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3    Development of Drug-Resistant Bacteria</title>
                     <text>
                        <paragraph>Prescribing SIVEXTRO in the absence of a proven or strongly suspected bacterial infection or prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="90f71098-22df-4fa5-afc1-1058976257ab"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20250404"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>The most common adverse reactions (≥2%) in adult patients are nausea, headache, diarrhea, infusion- or injection-related adverse reactions, vomiting, and dizziness. (<linkHtml href="#S6.1">6.1</linkHtml>)</item>
                           <item>The most common adverse reactions (&gt;2%) in pediatric patients (12 years to less than 18 years of age) are phlebitis and increased hepatic transaminases. (<linkHtml href="#S6.1">6.1</linkHtml>)</item>
                           <item>The most common adverse reactions (&gt;2%) in pediatric patients (less than 12 years of age) are infusion- or injection-related adverse reactions and vomiting. (<linkHtml href="#S6.1">6.1</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp &amp; Dohme LLC at 1-877-888-4231 or FDA at 1-800-FDA-1088 or <content styleCode="underline">
                                 <linkHtml href="#www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>
                              </content> .</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="daa04d51-6252-42dd-b6c3-542455fc761d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1    Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be compared directly to rates from clinical trials of another drug and may not reflect rates observed in practice.</paragraph>
                        <paragraph>
                           <content styleCode="bold underline">Clinical Trials Experience in Adult Patients</content>
                        </paragraph>
                        <paragraph>Adverse reactions were evaluated for 1425 adult patients treated with SIVEXTRO in two Phase 2 and four Phase 3 clinical trials (three Phase 3 trials for 6 days of therapy and one Phase 3 trial for 7-21 days of therapy). The median age of adult patients treated with SIVEXTRO in the Phase 2 and Phase 3 trials was 44 years, ranging between 17 and 94 years old. The majority of adult patients treated with SIVEXTRO were male (66%) and White (67%).</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                     <component>
                        <section>
                           <id root="44208dd6-5dc5-4855-b92c-d903c5acef5d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Serious Adverse Reactions and Adverse Reactions Leading to Discontinuation in Adults</content>
                              </paragraph>
                              <paragraph>Serious adverse reactions occurred in 37/1425 (2.6%) of adult patients treated with SIVEXTRO and in 25/1000 (2.5%) of adult patients treated with the comparator.  SIVEXTRO was discontinued due to an adverse reaction in 14/1425 (1%) of adult patients and the comparator was discontinued due to an adverse reaction in 13/1000 (1.3%) of adult patients.</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="bec2af29-6098-4f44-aa4f-0fa2197d0629"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Most Common Adverse Reactions in Adults</content>
                              </paragraph>
                              <paragraph>The most common adverse reactions in adult patients treated with SIVEXTRO were nausea (7.1%), headache (4.5%), diarrhea (3.6%), vomiting (2.7%), and dizziness (1.6%).  The median time of onset of adverse reactions was 5 days for both SIVEXTRO and linezolid with 12% occurring on the second day of treatment in both treatment groups.</paragraph>
                              <paragraph>
                                 <linkHtml href="#t5">Table 5</linkHtml> lists selected adverse reactions occurring in at least 2% of adult patients treated with SIVEXTRO in clinical trials.</paragraph>
                              <table width="80%" ID="t5">
                                 <caption>Table 5: Selected Adverse Reactions Occurring in ≥2% of Adult Patients Receiving SIVEXTRO in the Pooled Phase 3 ABSSSI Clinical Trials</caption>
                                 <col width="20%" align="left" valign="middle"/>
                                 <col width="40%" align="center" valign="middle"/>
                                 <col width="40%" align="center" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule" rowspan="2" align="left" valign="middle">Adverse  Reactions</th>
                                       <th styleCode="Rrule Botrule" colspan="2">Pooled Phase 3 ABSSSI Clinical Trials</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Rrule" align="center">SIVEXTRO<br/>(200 mg oral/intravenous once daily for 6 days)<br/>(N=1037)</th>
                                       <th styleCode="Rrule" align="center">Linezolid<br/>(600 mg oral/intravenous twice daily for 10 days)<br/>(N=1000)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="3">
                                          <content styleCode="bold">Gastrointestinal Disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Nausea</td>
                                       <td styleCode="Rrule">7%</td>
                                       <td styleCode="Rrule">10%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Diarrhea</td>
                                       <td styleCode="Rrule">4%</td>
                                       <td styleCode="Rrule">5%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Vomiting</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">5%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="3">
                                          <content styleCode="bold">Nervous System Disorder</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Headache</td>
                                       <td styleCode="Rrule">5%</td>
                                       <td styleCode="Rrule">5%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">  Dizziness</td>
                                       <td styleCode="Rrule">2%</td>
                                       <td styleCode="Rrule">2%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="3">
                                          <content styleCode="bold">Infusion- or Injection-Related Adverse Reactions</content>
                                          <footnote>Includes adverse reactions in the following body system or organ classes: General disorders and administration site conditions, infections and infestations, injury, poisoning and procedural complications, and vascular disorders, including but not limited to, phlebitis, injection- or infusion-site pain, injection- or infusion-site swelling, injection-site reaction, injection-site erythema, injection-site induration, and infusion-related reaction.</footnote>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule"/>
                                       <td styleCode="Rrule">4%</td>
                                       <td styleCode="Rrule">2%</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>The following selected adverse reactions were reported in SIVEXTRO-treated adult patients at a rate of less than 2% in these clinical trials:</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Blood and Lymphatic System Disorders:</content> anemia</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Cardiovascular:</content> palpitations, tachycardia</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Eye Disorders:</content> asthenopia, vision blurred, visual impairment, vitreous floaters</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Immune System Disorders:</content> drug hypersensitivity </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Infections and Infestations: </content>
                                 <content styleCode="italics">Clostridioides difficile</content> colitis, oral candidiasis, vulvovaginal mycotic infection</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Investigations:</content> hepatic transaminases increased (ALT increased, AST increased), gamma-glutamyltransferase (GGT) increased, white blood cell count decreased</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Nervous System Disorders:</content> hypoesthesia, paresthesia, VII<sup>th</sup> nerve paralysis</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Psychiatric Disorders:</content> insomnia</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Skin and Subcutaneous Tissue Disorders:</content> pruritus, urticaria, dermatitis</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Vascular Disorders:</content> flushing, hypertension</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="523d532e-4cab-40e7-a62a-e2bf4f3ce482"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Laboratory Parameters</content>
                              </paragraph>
                              <paragraph>Hematology laboratory abnormalities that were determined to be potentially clinically significant in the pooled Phase 3 ABSSSI clinical trials are provided in <linkHtml href="#t6">Table 6</linkHtml>.</paragraph>
                              <table width="80%" ID="t6">
                                 <caption>Table 6: Potentially Clinically Significant Lowest Laboratory Values in the Pooled Phase 3 ABSSSI Clinical Trials in Adults</caption>
                                 <col width="30%" align="left" valign="middle"/>
                                 <col width="35%" align="center" valign="middle"/>
                                 <col width="35%" align="center" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule" rowspan="2">Laboratory Assay</th>
                                       <th styleCode="Rrule Botrule" colspan="2">Potentially Clinically Significant Values<footnote>&lt;75% (&lt;50% for absolute neutrophil count) of lower limit of normal (LLN) for post-baseline measurements</footnote>
                                          <sup>,</sup>
                                          <footnote>Represents laboratory values within two days after the last dose of active drug</footnote>
                                       </th>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <th align="center" styleCode="Rrule">SIVEXTRO<br/>(200 mg oral/intravenous once daily for 6 days)<br/>(N)<footnote ID="F3">Number of subjects with at least one post-baseline test result that are within two days after the last dose of active drug</footnote>
                                       </th>
                                       <th align="center" styleCode="Rrule">Linezolid<br/>(600 mg oral/intravenous twice daily for 10 days)<br/>(N)<footnoteRef IDREF="F3"/>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" colspan="3">M = male; F = female</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hemoglobin<br/>  (&lt;10.1 g/dL [M])<br/>  (&lt;9 g/dL [F])</td>
                                       <td styleCode="Rrule">(994)<br/>3.4%</td>
                                       <td styleCode="Rrule">(957)<br/>3.4%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Platelet count<br/>  (&lt;112 × 10<sup>3</sup>/mm<sup>3</sup>)</td>
                                       <td styleCode="Rrule">(989)<br/>2.1%</td>
                                       <td styleCode="Rrule">(950)<br/>3.8%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Absolute neutrophil count<br/>  (&lt;0.8 × 10<sup>3</sup>/mm<sup>3</sup>)</td>
                                       <td styleCode="Rrule">(980)<br/>0.4%</td>
                                       <td styleCode="Rrule">(941)<br/>0.6%</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="a8b0b530-e4d4-4a27-b66e-03cbc35ad261"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Myelosuppression</content>
                              </paragraph>
                              <paragraph>Phase 1 studies conducted in healthy adults exposed to SIVEXTRO for 21 days showed a possible dose and duration effect on hematologic parameters beyond 6 days of treatment. In the Phase 3 trials, clinically significant changes in these parameters were generally similar for both treatment arms (see <linkHtml href="#t6">Table 6</linkHtml>). In postmarketing experience, thrombocytopenia has been reported in patients treated with SIVEXTRO. In one postmarketing report, patients who experienced thrombocytopenia were treated with tedizolid for a median duration of 26.5 days. <content styleCode="underline">A duration of treatment beyond 6 days is not approved</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="d026cdce-bbe8-4725-87cb-bc0e2f1f4aed"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Peripheral and Optic Neuropathy</content>
                              </paragraph>
                              <paragraph>Peripheral and optic neuropathy have been described in patients treated with another member of the oxazolidinone class for longer than 28 days. In Phase 3 trials in adults, reported adverse reactions for peripheral neuropathy and optic nerve disorders were similar between both treatment arms (peripheral neuropathy 1.2% vs. 0.7% for tedizolid phosphate and linezolid, respectively; optic nerve disorders 0.3% vs. 0.1%, respectively).  </paragraph>
                              <paragraph>
                                 <content styleCode="bold underline">Clinical Trials Experience in Pediatric Patients</content>
                              </paragraph>
                              <paragraph>SIVEXTRO was evaluated in 166 pediatric patients with ABSSSI in two randomized, active-controlled clinical trials, including one in patients aged 12 years to less than 18 years and one in patients aged 4 months to less than 12 years (Pediatric Trial 1 and Pediatric Trial 2, respectively). Additionally, SIVEXTRO was evaluated in 47 pediatric patients less than 2 years of age with a suspected or confirmed gram-positive bacterial infection in an open-label clinical trial (pediatric Trial 3).</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Pediatric Trial 1</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="underline">Adverse Reactions</content>
                              </paragraph>
                              <paragraph>Pediatric Trial 1 was a randomized, active-controlled, single-blind clinical trial that enrolled pediatric patients aged 12 to less than 18 years with ABSSSI. A total of 91 pediatric patients were treated with IV and/or oral SIVEXTRO 200 mg for 6 days and 29 patients were treated with a comparator agent for 10 days. The majority of pediatric patients treated with SIVEXTRO were male (64%) and white (88%).</paragraph>
                              <paragraph>Serious adverse reactions occurred in 1/91 (1%) of pediatric patients treated with SIVEXTRO and in none of the 29 patients treated with the comparator. Adverse reactions leading to discontinuation occurred in 1 (1%) pediatric patient in the SIVEXTRO arm and in none in the comparator arm.</paragraph>
                              <paragraph>The most common adverse reactions occurring in those receiving SIVEXTRO in Pediatric Trial 1 were phlebitis (3%), increased hepatic transaminases (alanine aminotransferase, aspartate aminotransferase) (3%), anemia (1%), and vomiting (1%).</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Laboratory Parameters</content>
                              </paragraph>
                              <table width="80%" ID="t7">
                                 <caption>Table 7: Potentially Clinically Significant Lowest Laboratory Values in the ABSSSI Clinical Trial in Pediatric Patients (12 to &lt;18 years)</caption>
                                 <col width="30%" align="left" valign="middle"/>
                                 <col width="35%" align="center" valign="middle"/>
                                 <col width="35%" align="center" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule" rowspan="2">Laboratory Assay</th>
                                       <th styleCode="Rrule Botrule" colspan="2">Potentially Clinically Significant Values<footnote ID="t4f1">&lt;75% (&lt;50% for absolute neutrophil count) of lower limit of normal (LLN) for post-baseline measurements</footnote>
                                          <sup>,</sup>
                                          <footnote ID="t4f2">Represents laboratory values within two days after the last dose of active drug</footnote>
                                       </th>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <th align="center" styleCode="Rrule">SIVEXTRO<br/>(200 mg oral/intravenous<br/>once daily for 6 days)
<br/>(N)<footnote ID="t4f3">Number of subjects with at least one post-baseline test result that are within two days after the last dose of active drug</footnote>
                                       </th>
                                       <th align="center" styleCode="Rrule">Comparators<footnote ID="t4f4">5 IV and 4 oral comparators selected per local standard of care</footnote>
                                          <br/>(for 10 days)<br/>(N)<footnoteRef IDREF="t4f3"/>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" colspan="3">M = male; F = female</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hemoglobin<br/>  (&lt;10.1 g/dL [M])<br/>  (&lt;9 g/dL [F])</td>
                                       <td styleCode="Rrule">(85)<br/>2.4%</td>
                                       <td styleCode="Rrule">(26)<br/>0.0%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Platelet count<br/>  (&lt;112 × 10<sup>3</sup>/mm<sup>3</sup>)</td>
                                       <td styleCode="Rrule">(82)<br/>1.2%</td>
                                       <td styleCode="Rrule">(26)<br/>0.0%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Absolute neutrophil count<br/>  (&lt;0.8 × 10<sup>3</sup>/mm<sup>3</sup>)</td>
                                       <td styleCode="Rrule">(85)<br/>0.0%</td>
                                       <td styleCode="Rrule">(26)<br/>0.0%</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>
                                 <content styleCode="bold">Pediatric Trial 2</content>
                              </paragraph>
                              <paragraph>Pediatric Trial 2 was a randomized, active-controlled, single-blind clinical trial that enrolled pediatric patients aged 4 months to less than 12 years with ABSSSI. A total of 75 patients were treated with IV and/or oral SIVEXTRO for 6 to 10 days and 25 were treated with a comparator agent for 10 to 14 days. The oral suspension formulation (currently not an approved formulation) was used in the clinical trial for those receiving oral therapy <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>].</content> The majority of patients treated with SIVEXTRO were male (53%) and white (77%), with a median age of 7 years and range of 0.3 to 11 years. The most common adverse reactions occurring in &gt;2% of patients receiving SIVEXTRO in Pediatric Trial 2 were infusion- or injection-related adverse reactions (including catheter site pain, catheter occlusion, infusion site extravasation, phlebitis; 5%), and vomiting (4%).</paragraph>
                              <paragraph>Potentially clinically significant laboratory abnormalities in Pediatric Trial 2 included one patient treated with SIVEXTRO who developed thrombocytopenia with platelet count less than 100 × 10<sup>3</sup>/mm<sup>3</sup>.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Pediatric Trial 3</content>
                              </paragraph>
                              <paragraph>Pediatric Trial 3 was an open-label, pharmacokinetic and safety trial enrolling 47 pediatric patients less than 2 years of age as follows: ages 28 days to less than 2 years (N=14), term neonates from birth to less than 28 days (N=16), and pre-term neonates (gestational age ≥ 26 weeks) from birth to less than 28 days (N=17). In this single-arm trial, 39 patients aged less than 2 years with a suspected or confirmed gram-positive bacterial infection received a single-dose of IV or oral SIVEXTRO and 8 patients aged less than 28 days with a suspected or confirmed gram-positive bacterial infection received multiple doses of IV SIVEXTRO for 3 days. The majority of patients were male (62%) and white (55%), with a median age of 16 days (range 1 day to 608 days).</paragraph>
                              <paragraph>The safety profile observed in this pediatric population was similar to that observed in Pediatric Trials 1 and 2.</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="7366a3c8-eb27-42d8-88d2-d0c365da161c"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post approval use of SIVEXTRO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Blood and Lymphatic System Disorders</content>:</content> thrombocytopenia</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="6cbadc53-e720-4895-95dd-33edeee1c075"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>Orally administered SIVEXTRO inhibits Breast Cancer Resistance Protein (BCRP) in the intestine, which can increase the plasma concentrations of orally administered BCRP substrates, and the potential for adverse reactions.  If possible, an interruption in the treatment of the co-administered BCRP substrate medicinal product should be considered during treatment with SIVEXTRO, especially for BCRP substrates with a narrow therapeutic index (e.g., methotrexate or topotecan). If coadministration cannot be avoided, monitor for adverse reactions related to the concomitantly administered BCRP substrates, including rosuvastatin. <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>.]</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250404"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>SIVEXTRO (when administered orally) can increase the plasma concentrations of orally administered Breast Cancer Resistance Protein (BCRP) substrates. Monitor for adverse reactions related to the concomitant BCRP substrates if coadministration cannot be avoided. (<linkHtml href="#S7">7</linkHtml>, <linkHtml href="#S12.3">12.3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="bf47d8eb-b4c3-4b22-ad5a-b22283e1c26a"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250404"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Pregnancy: Based on animal data, SIVEXTRO may cause fetal harm. Advise pregnant women of the potential risks to a fetus. (<linkHtml href="#S8.1">8.1</linkHtml>)<br/>
                           <br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="8e307aeb-3cce-48e3-84c4-d798378f5761"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250404"/>
                     <component>
                        <section>
                           <id root="6bffc1c7-95d8-481a-a3bd-368a2a8b688b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Risk Summary</content>
                              </paragraph>
                              <paragraph>Based on animal reproduction studies, SIVEXTRO may cause fetal harm when administered to pregnant women. The available data on the use of SIVEXTRO in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Advise pregnant women of the potential risks to a fetus. Fetal developmental toxicities were observed in mice and rats treated with SIVEXTRO. In embryo-fetal studies in mice and rats, tedizolid phosphate was shown to produce fetal developmental toxicities in mice and maternal toxicity and fetal developmental toxicities in rats. Tedizolid phosphate administered orally during organogenesis to pregnant animals was associated with reduced fetal weights and an increased incidence of costal cartilage anomalies in the absence of maternal toxicity in mice; and maternal toxicity, decreased fetal weights, and increased skeletal variations in rats at plasma exposures approximately 4 and 6 times respectively, the human plasma exposure at the maximum recommended human dose (MRHD) of 200 mg/day. In female rats administered tedizolid phosphate during organogenesis through lactation, there was no evidence of fetal toxicity, developmental delays, or impaired reproduction in the offspring at plasma exposures approximately equivalent to the human plasma exposure at the MRHD. <content styleCode="italics">(see <linkHtml href="#data">Data</linkHtml>)</content>
                              </paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. </paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="93268ab3-0354-4585-9bf8-c345f44cab12"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                           <component>
                              <section>
                                 <id root="9181e2cc-0a41-4ccc-a25e-ad4a13471bc1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="bold italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>In an embryo-fetal development study, tedizolid phosphate administered orally to pregnant mice at doses of 1, 5, and 25 mg/kg/day during organogenesis (Gestational Day [GD] 6 to GD15) was associated with fetal developmental effects occurring in the absence of maternal toxicity, including reduced fetal weights and an increased incidence of costal cartilage anomalies at the high dose (approximately 4-times the human plasma exposure at the MRHD based on plasma AUC comparison). Tedizolid phosphate administered orally at doses of 2.5, 5, and 15 mg/kg/day to pregnant rats during organogenesis (GD6 through GD17) was associated with maternal toxicity (reduced maternal body weights), decreased fetal weights, and increased skeletal variations including reduced ossification of the sternebrae, vertebrae, and skull at the high dose of 15 mg/kg/day (approximately 6-times the human plasma exposure at the MRHD based on plasma AUC comparison). The doses not associated with fetal toxicity in mice and maternal and fetal toxicity in rats were 5 and 2.5 mg/kg/day respectively (for both species approximately equivalent to the human plasma exposure at the MRHD based on plasma AUC comparison). </paragraph>
                                    <paragraph>In a pre-postnatal study, oral tedizolid phosphate administered to female rats at doses of 1.25, 2.5, and 3.75 mg/kg/day during gestation and lactation (GD6 through Lactational Day 20) was not associated with maternal toxicity, fetal toxicity, developmental delays, or impaired reproduction at doses up to the high dose of 3.75 mg/kg/day (approximately equivalent to the human plasma exposure at the MRHD based on plasma AUC comparison).</paragraph>
                                 </text>
                                 <effectiveTime value="20250404"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="ca6713df-6ba4-465b-883d-fe464da7a5f2"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20250404"/>
                     <component>
                        <section>
                           <id root="3698ac7f-e351-4da2-9fc6-9033ddec6d64"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Risk Summary</content>
                              </paragraph>
                              <paragraph>There is no information on the presence of tedizolid in human milk. Tedizolid is present in rat milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk. There are no data on the effects of SIVEXTRO on the breastfed child or on milk production.</paragraph>
                              <paragraph>The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for SIVEXTRO and any potential adverse effects on the breastfed child from SIVEXTRO or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="36bd2448-17de-4064-bdc1-1ee08098ff1b"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of SIVEXTRO for the treatment of ABSSSI have been established in pediatric patients at least 26 weeks gestational age and weighing at least 1 kg. Use of SIVEXTRO for the treatment of ABSSSI is supported by evidence from adequate and well-controlled studies in adults with additional pharmacokinetic and safety data in pediatric patients from birth (includes neonates at least 26 weeks gestational age) to less than 18 years of age <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>, and <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>The safety and effectiveness of SIVEXTRO in pediatric patients less than 26 weeks gestational age and weighing less than 1 kg have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="836aaf93-a05c-4430-b3e0-72b556675ee4"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of SIVEXTRO did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.  No overall differences in pharmacokinetics were observed between elderly subjects and younger subjects.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="cc4614ef-2ef8-4451-8b21-d3cfafba607e"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>In the event of overdosage, SIVEXTRO should be discontinued and general supportive treatment given.  Hemodialysis does not result in meaningful removal of tedizolid from systemic circulation.</paragraph>
               </text>
               <effectiveTime value="20250404"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="3e9a1de4-cc5c-4080-8cec-4adf6f38edfe"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>SIVEXTRO (tedizolid phosphate), a phosphate prodrug, is converted to tedizolid in the presence of phosphatases.</paragraph>
                  <paragraph>Tedizolid phosphate has the chemical name [(5<content styleCode="italics">R</content>)-(3-{3-Fluoro-4-[6-(2-methyl-2<content styleCode="italics">H</content>-tetrazol- 5-yl) pyridin-3-yl]phenyl}-2-oxooxazolidin- 5-yl]methyl hydrogen phosphate.</paragraph>
                  <paragraph>Its empirical formula is C<sub>17</sub>H<sub>16</sub>FN<sub>6</sub>O<sub>6</sub>P and its molecular weight is 450.32.  Its structural formula is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>Tedizolid phosphate is a white to yellow solid and is administered orally or by intravenous infusion.</paragraph>
                  <paragraph>The pharmacologically active moiety, tedizolid, is an antibacterial agent of the oxazolidinone class.</paragraph>
                  <paragraph>SIVEXTRO Tablets contain 200 mg of tedizolid phosphate, and the following inactive ingredients: crospovidone, magnesium stearate, mannitol, microcrystalline cellulose, and povidone. In addition, the film coating contains the following inactive ingredients: polyethylene glycol/macrogol, polyvinyl alcohol, talc, titanium dioxide, and yellow iron oxide.</paragraph>
                  <paragraph>SIVEXTRO for Injection is a sterile, white to off-white sterile lyophilized powder supplied in a clear glass single-dose vial. Each vial contains 200 mg of tedizolid phosphate and the inactive ingredient, mannitol (105 mg). Sodium hydroxide and hydrochloric acid are used as needed for pH adjustment. When reconstituted as directed with 4 mL of Sterile Water for Injection, each mL contains 50 mg of tedizolid phosphate. The pH of the reconstituted solution is 7.4 to 8.1.</paragraph>
               </text>
               <effectiveTime value="20250404"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="sivextro-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="ad16c7f5-e22b-4aae-8cea-cae5a5eecdbe"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250404"/>
               <component>
                  <section ID="S12.1">
                     <id root="33de8de4-4411-40cb-83e2-26e573df42cf"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Tedizolid is an antibacterial drug <content styleCode="italics">[see <linkHtml href="#S12.4">Microbiology (12.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="4f172b5d-a55d-4ebb-bdb4-ae0cd6bf96ad"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>The AUC/minimum inhibitory concentration (MIC) was shown to best correlate with tedizolid activity in animal infection models.</paragraph>
                        <paragraph>In the mouse thigh infection model of <content styleCode="italics">S. aureus</content>, antistaphylococcal killing activity was impacted by the presence of granulocytes.  In granulocytopenic mice (neutrophil count &lt;100 cells/mL), bacterial stasis was achieved at a human-equivalent dose of approximately 2000 mg/day; whereas, in non-granulocytopenic animals, stasis was achieved at a human-equivalent dose of approximately 100 mg/day.  The safety and efficacy of SIVEXTRO for the treatment of neutropenic patients (neutrophil counts &lt;1000 cells/mm<sup>3</sup>) have not been evaluated. </paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                     <component>
                        <section>
                           <id root="c0097814-11ef-4411-a589-3daee14a5bf4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Cardiac Electrophysiology </content>
                              </paragraph>
                              <paragraph>In a randomized, positive- and placebo-controlled crossover thorough QTc study, 48 enrolled subjects were administered a single oral dose of SIVEXTRO at a therapeutic dose of 200 mg, SIVEXTRO at a supratherapeutic dose of 1200 mg, placebo, and a positive control; no significant effects of SIVEXTRO on heart rate, electrocardiogram morphology, PR, QRS, or QT interval were detected.  Therefore, SIVEXTRO does not affect cardiac repolarization.</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="f8ba6954-7ab6-4022-9591-c6ce7404d5ae"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Tedizolid phosphate is a prodrug that is converted by phosphatases to tedizolid, the microbiologically active moiety, following oral and intravenous administration.  Only the pharmacokinetic profile of tedizolid is discussed further due to negligible systemic exposure of tedizolid phosphate following oral and intravenous administration. Following multiple once-daily oral or intravenous administration, steady-state concentrations are achieved within approximately three days with tedizolid accumulation of approximately 30% (tedizolid half-life of approximately 12 hours). Pharmacokinetic (PK) parameters of tedizolid following oral and intravenous administration of 200 mg once daily tedizolid phosphate in adults are shown in <linkHtml href="#t8">Table 8</linkHtml>.</paragraph>
                        <table width="100%" ID="t8">
                           <caption>Table 8: Mean (Standard Deviation) Tedizolid Pharmacokinetic Parameters Following Single and Multiple Oral and Intravenous Administration of 200 mg Once-Daily Tedizolid Phosphate in Adults</caption>
                           <col width="24%" align="left" valign="middle"/>
                           <col width="19%" align="center" valign="middle"/>
                           <col width="19%" align="center" valign="middle"/>
                           <col width="19%" align="center" valign="middle"/>
                           <col width="19%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" rowspan="2">Pharmacokinetic Parameters of Tedizolid<footnote>C<sub>max</sub>, maximum concentration; T<sub>max</sub>, time to reach C<sub>max</sub>; AUC, area under the concentration-time curve; CL, systemic clearance; CL/F, apparent oral clearance</footnote>
                                 </th>
                                 <th styleCode="Rrule Botrule" colspan="2">Oral</th>
                                 <th styleCode="Rrule Botrule" colspan="2">Intravenous</th>
                              </tr>
                              <tr styleCode="Botrule">
                                 <th align="center" styleCode="Rrule">Single Dose</th>
                                 <th styleCode="Rrule">Steady State</th>
                                 <th styleCode="Rrule">Single Dose</th>
                                 <th styleCode="Rrule">Steady State</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">C<sub>max </sub>(mcg/mL)</td>
                                 <td styleCode="Rrule">2.0 (0.7)</td>
                                 <td styleCode="Rrule">2.2 (0.6)</td>
                                 <td styleCode="Rrule">2.3 (0.6)</td>
                                 <td styleCode="Rrule">3.0 (0.7)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">T<sub>max </sub>(hr)<footnote>Median (range)</footnote>
                                 </td>
                                 <td styleCode="Rrule">2.5 (1.0 - 8.0)</td>
                                 <td styleCode="Rrule">3.5 (1.0 - 6.0)</td>
                                 <td styleCode="Rrule">1.1 (0.9 - 1.5)</td>
                                 <td styleCode="Rrule">1.2 (0.9 - 1.5)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">AUC (mcg<content styleCode="bold">∙</content>hr/mL)<footnote>AUC is AUC<sub>0-</sub>
                                       <sub>∞</sub> (AUC from time 0 to infinity) for single-dose administration and AUC<sub>0-24 </sub>(AUC from time 0 to 24 hours) for multiple-dose administration</footnote>
                                 </td>
                                 <td styleCode="Rrule">23.8 (6.8)</td>
                                 <td styleCode="Rrule">25.6 (8.5)</td>
                                 <td styleCode="Rrule">26.6 (5.2)</td>
                                 <td styleCode="Rrule">29.2 (6.2)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">CL or CL/F (L/hr)</td>
                                 <td styleCode="Rrule">7.5 (2.3)</td>
                                 <td styleCode="Rrule">6.9 (1.7)</td>
                                 <td styleCode="Rrule">6.4 (1.2)</td>
                                 <td styleCode="Rrule">5.9 (1.4)</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250404"/>
                     <component>
                        <section>
                           <id root="dca43271-c140-4500-82fc-8ecae3c106fc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Absorption</content>
                              </paragraph>
                              <paragraph>Peak plasma tedizolid concentrations are achieved within approximately 3 hours following oral administration of the oral tablet under fasting conditions or at the end of the 1 hour intravenous infusion of tedizolid phosphate. The absolute bioavailability of the oral tablet is approximately 91% and no dosage adjustment is necessary between intravenous and oral administration.</paragraph>
                              <paragraph>Tedizolid phosphate (oral tablet) may be administered with or without food as total systemic exposure (AUC<sub>0-∞</sub>) is unchanged between fasted and fed (high-fat, high-calorie) conditions.</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="4f3bdb27-c011-461f-b834-359cb8cfded0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Distribution</content>
                              </paragraph>
                              <paragraph>Protein binding of tedizolid to human plasma proteins is approximately 70 to 90%. The mean steady state volume of distribution of tedizolid in healthy adults following a single intravenous dose of tedizolid phosphate 200 mg ranged from 67 to 80 L (approximately twice total body water). Tedizolid penetrates into the interstitial space fluid of adipose and skeletal muscle tissue with exposure similar to free drug exposure in plasma.</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="474b623d-0c1f-4212-8eb6-6ddb48ea7e44"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Elimination</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                           <component>
                              <section>
                                 <id root="f3d14178-e1ce-4672-96b9-2553aae9ede1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="bold italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>Other than tedizolid, which accounts for approximately 95% of the total radiocarbon AUC in plasma, there are no other significant circulating metabolites in humans.</paragraph>
                                    <paragraph>There was no degradation of tedizolid in human liver microsomes indicating tedizolid is unlikely to be a substrate for hepatic CYP450 enzymes.</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">In vitro</content> studies showed that conjugation of tedizolid is mediated via multiple sulfotransferase (SULT) isoforms (SULT1A1, SULT1A2, and SULT2A1).</paragraph>
                                 </text>
                                 <effectiveTime value="20250404"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="42806e3b-d011-43c6-b811-6920ebbf7e1f"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="bold italics">Excretion</content>
                                    </paragraph>
                                    <paragraph>Following single oral administration of 14C-labeled tedizolid phosphate under fasted conditions in adult healthy volunteers, the majority of elimination occurred via the liver, with 82% of the radioactive dose recovered in feces and 18% in urine, primarily as a non-circulating and microbiologically inactive sulfate conjugate. Most of the elimination of tedizolid (&gt;85%) occurs within 96 hours.  Less than 3% of the tedizolid phosphate-administered dose is excreted in feces and urine as unchanged tedizolid.</paragraph>
                                 </text>
                                 <effectiveTime value="20250404"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="45457106-b28d-4b86-bc1e-cfb9bebaf71d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Specific Populations</content>
                              </paragraph>
                              <paragraph>Based on the population pharmacokinetic analysis, there are no clinically relevant demographic or clinical patient factors (including age, gender, race, ethnicity, weight, body mass index, and measures of renal or liver function) that impact the pharmacokinetics of tedizolid.</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                           <component>
                              <section>
                                 <id root="61acd2d8-d8d8-4c1f-bd2c-b91a18da8e71"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="bold italics">Patients with Hepatic Impairment</content>
                                    </paragraph>
                                    <paragraph>Following administration of a single 200 mg oral dose of SIVEXTRO, no clinically meaningful changes in mean tedizolid C<sub>max</sub> and AUC<sub>0-</sub>
                                       <sub>∞</sub> were observed in adult patients with moderate (n=8) or severe (n=8) hepatic impairment (Child-Pugh Class B and C) compared to 8 matched healthy control subjects.  No dose adjustment is necessary for patients with hepatic impairment.</paragraph>
                                 </text>
                                 <effectiveTime value="20250404"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="955b6143-b47d-43d8-9e51-2b69016e085f"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="bold italics">Patients with Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>Following administration of a single 200 mg intravenous dose of SIVEXTRO to 8 adult subjects with severe renal impairment defined as eGFR &lt;30 mL/min/1.73 m<sup>2</sup>, the C<sub>max</sub> was essentially unchanged and AUC<sub>0-</sub>
                                       <sub>∞</sub> was decreased by less than 10% compared to 8 matched healthy control adult subjects.  Hemodialysis does not result in meaningful removal of tedizolid from systemic circulation, as assessed in subjects with end-stage renal disease (eGFR &lt;15 mL/min/1.73 m<sup>2</sup>).  No dosage adjustment is necessary in patients with renal impairment or patients on hemodialysis.</paragraph>
                                 </text>
                                 <effectiveTime value="20250404"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="800eb3f9-d6d4-4219-b0c3-329891aa51c9"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="bold italics">Geriatric Patients</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetics of tedizolid were evaluated in a Phase 1 study conducted in elderly healthy volunteers (age 65 years and older, with at least 5 subjects at least 75 years old; n=14) compared to younger control subjects (25 to 45 years old; n=14) following administration of a single oral dose of SIVEXTRO 200 mg.  There were no clinically meaningful differences in tedizolid C<sub>max</sub> and AUC<sub>0-</sub>
                                       <sub>∞</sub> between elderly subjects and younger control subjects.  No dosage adjustment of SIVEXTRO is necessary in elderly patients.</paragraph>
                                 </text>
                                 <effectiveTime value="20250404"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3067b61b-f076-4c45-8733-20125c9888a5"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="bold italics">Male and Female Patients</content>
                                    </paragraph>
                                    <paragraph>The impact of gender on the pharmacokinetics of SIVEXTRO was evaluated in clinical trials of adult healthy males and females and in a population pharmacokinetics analysis.  The pharmacokinetics of tedizolid were similar in males and females.  No dosage adjustment of SIVEXTRO is necessary based on gender.</paragraph>
                                    <paragraph>
                                       <content styleCode="bold italics">Pediatric Patients</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetics of tedizolid was evaluated in clinical studies in pediatric patients from birth (includes neonates who are at least 26 weeks gestational age and weighing at least 1 kg) to less than 18 years of age (N=249).</paragraph>
                                    <paragraph>Compared to adult patients, tedizolid exposures are higher in pediatric patients (12 to &lt;18 years of age, mean weight: 59.7 kg, weight range: 28 kg to 126 kg in Pediatric Trial 1) following multiple dose administration of a once daily dose of 200 mg IV or oral SIVEXTRO (geometric mean C<sub>max</sub> 3.1 vs. 2.0 mcg/mL, AUC<sub>24h</sub> 28.6 vs. 21.0 mcg*h/mL); however, this increase in exposure is not considered clinically significant.</paragraph>
                                    <paragraph>The predicted steady state mean pharmacokinetic parameters of tedizolid by the pediatric weight-based dosage in <linkHtml href="#t2">Table 2</linkHtml> and <linkHtml href="#t3">Table 3</linkHtml> are shown in <linkHtml href="#t9">Table 9</linkHtml>.</paragraph>
                                    <table width="100%" ID="t9">
                                       <caption>Table 9: Geometric Mean (% CV) Predicted Steady-State Exposures Following Multiple Dose Administration of IV or Oral Tedizolid Phosphate Based Upon the Weight-Banded Dosage in Pediatric Patients Birth<footnote ID="t9f1">Pediatric patients from birth (includes neonates at least 26 weeks gestational age).</footnote> to Less than 18 Years</caption>
                                       <colgroup>
                                          <col width="18%" align="center" valign="middle"/>
                                          <col width="14%" align="center" valign="middle"/>
                                          <col width="14%" align="center" valign="middle"/>
                                          <col width="8%" align="center" valign="middle"/>
                                          <col width="20%" align="center" valign="middle"/>
                                          <col width="26%" align="center" valign="middle"/>
                                       </colgroup>
                                       <thead>
                                          <tr>
                                             <th styleCode="Lrule Rrule">Weight (kg)</th>
                                             <th styleCode="Rrule">Dosage Regimen</th>
                                             <th styleCode="Rrule">Total Daily Dose</th>
                                             <th styleCode="Rrule">Route</th>
                                             <th styleCode="Rrule">Steady-State AUC<sub>24h</sub> (mcg·h/mL)<footnote ID="t9f2">AUC<sub>0-24</sub> = 2 X AUC<sub>0-12</sub> for twice daily dosing.</footnote>
                                             </th>
                                             <th styleCode="Rrule">Steady-State C<sub>max</sub> (mcg/mL)</th>
                                          </tr>
                                       </thead>
                                       <tfoot>
                                          <tr>
                                             <td align="left" colspan="6">AUC, area under the concentration-time curve; C<sub>max</sub>, maximum concentration; %CV, coefficient of variation.</td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">1 to less than 2</td>
                                             <td styleCode="Rrule">3 mg/kg <br/>Twice daily</td>
                                             <td styleCode="Rrule">6 mg to less than12 mg</td>
                                             <td styleCode="Rrule">IV</td>
                                             <td styleCode="Rrule">33.1 (29.8)</td>
                                             <td styleCode="Rrule">2.3 (17.2)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">2 to less than 3</td>
                                             <td styleCode="Rrule">6 mg <br/>Twice daily</td>
                                             <td styleCode="Rrule">12 mg</td>
                                             <td styleCode="Rrule">IV</td>
                                             <td styleCode="Rrule">20.8 (25.6)</td>
                                             <td styleCode="Rrule">1.8 (15.9)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">3 to less than 6</td>
                                             <td styleCode="Rrule">12 mg<br/>
Twice daily</td>
                                             <td styleCode="Rrule">24 mg</td>
                                             <td styleCode="Rrule">IV</td>
                                             <td styleCode="Rrule">26.4 (34.4)</td>
                                             <td styleCode="Rrule">2.4 (20.7)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">6 to less than 10</td>
                                             <td styleCode="Rrule">20 mg<br/>
Twice daily</td>
                                             <td styleCode="Rrule">40 mg</td>
                                             <td styleCode="Rrule">IV</td>
                                             <td styleCode="Rrule">22.5 (43.9)</td>
                                             <td styleCode="Rrule">2.2 (20.4)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">10 to less than 14</td>
                                             <td styleCode="Rrule">30 mg<br/>
Twice daily</td>
                                             <td styleCode="Rrule">60 mg</td>
                                             <td styleCode="Rrule">IV</td>
                                             <td styleCode="Rrule">27.6 (32.1)</td>
                                             <td styleCode="Rrule">2.7 (19.6)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">14 to less than 20</td>
                                             <td styleCode="Rrule">40 mg<br/>
Twice daily</td>
                                             <td styleCode="Rrule">80 mg</td>
                                             <td styleCode="Rrule">IV</td>
                                             <td styleCode="Rrule">28.4 (22.1)</td>
                                             <td styleCode="Rrule">2.7 (13.0)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">20 to less than 35</td>
                                             <td styleCode="Rrule">60 mg<br/>
Twice daily</td>
                                             <td styleCode="Rrule">120 mg</td>
                                             <td styleCode="Rrule">IV</td>
                                             <td styleCode="Rrule">31.4 (29.9)</td>
                                             <td styleCode="Rrule">2.6 (21.6)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" rowspan="2">At least 35</td>
                                             <td styleCode="Rrule" rowspan="2">200 mg<br/>Once daily</td>
                                             <td styleCode="Rrule" rowspan="2">200 mg</td>
                                             <td styleCode="Rrule">IV</td>
                                             <td styleCode="Rrule">30.6 (29.7)</td>
                                             <td styleCode="Rrule">3.8 (23.9)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Oral (tablet)</td>
                                             <td styleCode="Rrule">29.3 (29.7)</td>
                                             <td styleCode="Rrule">2.5 (24.4)</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20250404"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2135a92b-788b-48de-80ff-a0cace662032"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Drug Interaction Studies</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                           <component>
                              <section>
                                 <id root="b9bcfd26-ecb3-4620-baa8-e53cb234e8da"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="bold italics">Drug Metabolizing Enzymes</content>
                                    </paragraph>
                                    <paragraph>Transformation via Phase 1 hepatic oxidative metabolism is not a significant pathway for elimination of SIVEXTRO.</paragraph>
                                    <paragraph>Neither SIVEXTRO nor tedizolid detectably inhibited or induced the metabolism of selected CYP enzyme substrates, suggesting that drug-drug interactions based on oxidative metabolism are unlikely.</paragraph>
                                 </text>
                                 <effectiveTime value="20250404"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="bc44c73d-b325-4305-87d4-83b5f1b25f6c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="bold italics">Membrane Transporters</content>
                                    </paragraph>
                                    <paragraph>The potential for tedizolid or tedizolid phosphate to inhibit transport of probe substrates of important drug uptake (OAT1, OAT3, OATP1B1, OATP1B3, OCT1, and OCT2) and efflux transporters (P-gp and BCRP) was tested <content styleCode="italics">in vitro</content>.  No clinically relevant interactions are expected to occur with these transporters except BCRP.</paragraph>
                                    <paragraph>Coadministration of multiple oral doses of SIVEXTRO (200 mg once daily) increased the C<sub>max</sub> and AUC of rosuvastatin (10 mg single oral dose), a known BCRP substrate, by approximately 55% and 70%, respectively, in healthy adult subjects <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20250404"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="8e736b22-4c10-4436-9c95-39de8a5e8dad"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="bold italics">Monoamine Oxidase Inhibition </content>
                                    </paragraph>
                                    <paragraph>Tedizolid is a reversible inhibitor of monoamine oxidase (MAO) <content styleCode="italics">in vitro</content>.  The interaction with MAO inhibitors could not be evaluated in Phase 2 and 3 trials, as subjects taking such medications were excluded from the trials.</paragraph>
                                 </text>
                                 <effectiveTime value="20250404"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="df872213-f23f-4d55-a44a-f5efabd2a0a9"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="bold italics">Adrenergic Agents</content>
                                    </paragraph>
                                    <paragraph>Two placebo-controlled crossover studies were conducted to assess the potential of 200 mg oral SIVEXTRO at steady state to enhance pressor responses to pseudoephedrine and tyramine in healthy adults.  No meaningful changes in blood pressure or heart rate were seen with pseudoephedrine.  The median tyramine dose required to cause an increase in systolic blood pressure of ≥30 mmHg from pre-dose baseline was 325 mg with SIVEXTRO compared to 425 mg with placebo.  Palpitations were reported in 21/29 (72.4%) adult subjects exposed to SIVEXTRO compared to 13/28 (46.4%) exposed to placebo in the tyramine challenge study.</paragraph>
                                 </text>
                                 <effectiveTime value="20250404"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="7cbadc8e-0391-4411-9212-df0685129082"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="bold italics">Serotonergic Agents</content>
                                    </paragraph>
                                    <paragraph>Serotonergic effects at doses of tedizolid phosphate up to 30-fold above the human equivalent dose did not differ from vehicle control in a mouse model that predicts serotonergic activity. In Phase 3 trials, subjects taking serotonergic agents including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, and serotonin 5-hydroxytryptamine (5-HT1) receptor agonists (triptans), meperidine, or buspirone were excluded.</paragraph>
                                 </text>
                                 <effectiveTime value="20250404"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.4">
                     <id root="622e78f0-230a-4b28-989d-c873599d7d0c"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4 Microbiology</title>
                     <effectiveTime value="20250404"/>
                     <component>
                        <section>
                           <id root="432f53e8-ee6b-435b-8102-86a31207bffa"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Mechanism of Action</content>
                              </paragraph>
                              <paragraph>The antibacterial activity of tedizolid is mediated by binding to the 50S subunit of the bacterial ribosome resulting in inhibition of protein synthesis.  Tedizolid inhibits bacterial protein synthesis through a mechanism of action different from that of other non-oxazolidinone class antibacterial drugs; therefore, cross-resistance between tedizolid and other classes of antibacterial drugs is unlikely.  The results of <content styleCode="italics">in vitro</content> time-kill studies show that tedizolid is bacteriostatic against enterococci, staphylococci, and streptococci.</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="5eede485-a588-46f4-87dc-3100a356fbad"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Resistance</content>
                              </paragraph>
                              <paragraph>Organisms resistant to oxazolidinones via mutations in chromosomal genes encoding 23S rRNA or ribosomal proteins (L3 and L4) are generally cross-resistant to tedizolid.  In the limited number of <content styleCode="italics">Staphylococcus aureus</content> strains tested, the presence of the chloramphenicol-florfenicol resistance (<content styleCode="italics">cfr</content>) gene did not result in resistance to tedizolid in the absence of chromosomal mutations. Mutations in 23SrRNA (G2576T mutation) have been associated with tedizolid resistance in <content styleCode="italics">S. aureus </content>isolates.</paragraph>
                              <paragraph>Spontaneous mutations conferring reduced susceptibility to tedizolid occur <content styleCode="italics">in vitro</content> at a frequency rate of approximately 10<sup>-10</sup>.</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="7fdb51fa-752c-4abc-b39e-b690bec563b3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Interaction with Other Antimicrobial Drugs</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">In vitro</content> drug combination studies with tedizolid and aztreonam, ceftriaxone, ceftazidime, imipenem, rifampin, trimethoprim/sulfamethoxazole, minocycline, clindamycin, ciprofloxacin, daptomycin, vancomycin, gentamicin, amphotericin B, ketoconazole, and terbinafine demonstrate neither synergy nor antagonism.</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="e40f0cde-058f-412b-bc76-dd6b1c06f7cd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Antimicrobial Activity</content>
                              </paragraph>
                              <paragraph>Tedizolid has been shown to be active against most isolates of the following bacteria, both <content styleCode="italics">in vitro</content> and in clinical infections, as described in <content styleCode="italics">
                                    <linkHtml href="#S1">Indications and Usage (1)</linkHtml>
                                 </content>.</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="0dc328c1-ba0d-4b50-b78b-ebb06edd0157"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Aerobic bacteria</content>
                              </paragraph>
                              <paragraph>    Gram-positive bacteria</paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption> </caption>
                                    <content styleCode="italics">Staphylococcus aureus </content>(including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates)</item>
                                 <item>
                                    <caption> </caption>
                                    <content styleCode="italics">Streptococcus pyogenes</content>
                                 </item>
                                 <item>
                                    <caption> </caption>
                                    <content styleCode="italics">Streptococcus agalactiae</content>
                                 </item>
                                 <item>
                                    <caption> </caption>
                                    <content styleCode="italics">Streptococcus anginosus </content>Group (including <content styleCode="italics">S. anginosus</content>, <content styleCode="italics">S. intermedius</content>, and <content styleCode="italics">S. constellatus</content>) 												</item>
                                 <item>
                                    <caption> </caption>
                                    <content styleCode="italics">Enterococcus faecalis</content>
                                 </item>
                              </list>
                              <paragraph>The following <content styleCode="italics">in vitro</content> data are available, but their clinical significance is unknown. At least 90% of the following bacteria exhibit an <content styleCode="italics">in vitro</content> minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for tedizolid against isolates of similar genus or organism group. However, the efficacy of SIVEXTRO in treating clinical infections caused by these bacteria has not been established in adequate and well-controlled clinical trials.</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="abc0b6cf-69f1-41a4-aed8-2e926a201e72"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Aerobic bacteria</content>
                              </paragraph>
                              <paragraph>
                                     Gram-positive bacteria
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption> </caption>
                                    <content styleCode="italics">Staphylococcus epidermidis</content> (including methicillin-susceptible and methicillin-resistant isolates)</item>
                                 <item>
                                    <caption> </caption>
                                    <content styleCode="italics">Staphylococcus haemolyticus</content>
                                 </item>
                                 <item>
                                    <caption> </caption>
                                    <content styleCode="italics">Staphylococcus lugdunensis</content>
                                 </item>
                                 <item>
                                    <caption> </caption>
                                    <content styleCode="italics">Enterococcus faecium </content>
                                 </item>
                              </list>
                           </text>
                           <effectiveTime value="20250404"/>
                           <component>
                              <section>
                                 <id root="aca30881-c2d4-4f20-852b-68fcd7cf1876"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Susceptibility Testing</content>
                                    </paragraph>
                                    <paragraph>For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC</paragraph>
                                 </text>
                                 <effectiveTime value="20250404"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="b78f5f19-3c3a-4c87-ae9f-06ebea3d6141"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250404"/>
               <component>
                  <section ID="S13.1">
                     <id root="d458c5c8-e3a4-4068-8685-fca306069661"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20250404"/>
                     <component>
                        <section>
                           <id root="ad0d4d1e-45ca-4566-92ea-1d471e3ae6de"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Carcinogenicity</content>
                              </paragraph>
                              <paragraph>Long-term carcinogenicity studies have not been conducted with tedizolid phosphate.</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="efc8bc1f-6861-42d0-807f-12e8fc6b55d6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Tedizolid phosphate was negative for genotoxicity in all <content styleCode="italics">in vitro</content> assays (bacterial reverse mutation (Ames), Chinese hamster lung (CHL) cell chromosomal aberration) and in all <content styleCode="italics">in vivo</content> tests (mouse bone marrow micronucleus, rat liver unscheduled DNA synthesis). Tedizolid, generated from tedizolid phosphate after metabolic activation (<content styleCode="italics">in vitro</content> and <content styleCode="italics">in vivo</content>), was also tested for genotoxicity. Tedizolid was positive in an <content styleCode="italics">in vitro</content> CHL cell chromosomal aberration assay, but negative for genotoxicity in other <content styleCode="italics">in vitro</content> assays (Ames, mouse lymphoma mutagenicity) and <content styleCode="italics">in vivo</content> in a mouse bone marrow micronucleus assay.</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="5b15f6f6-f207-4d38-9c72-aeb369d9f0fe"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>In a fertility study, oral tedizolid phosphate administered in doses of 5, 15, and 50 mg/kg/day for 28 days before mating and during mating to male rats had no adverse effects on the fertility or reproductive performance, including spermatogenesis, at the maximum tested dose (50 mg/kg/day) with a plasma tedizolid AUC approximately 5-fold greater than the plasma AUC value in humans at the maximum recommended human dose (MRHD). Tedizolid phosphate administered in doses of 2.5, 5, and 15 mg/kg/day for 14 days before mating, during mating, and until Gestation Day (GD)7 to female rats also had no adverse effects on the fertility or reproductive performance at doses up to the maximum tested dose of 15 mg/kg/day (approximately 4-fold higher than exposures in humans at the MRHD based on plasma AUC comparison).</paragraph>
                           </text>
                           <effectiveTime value="20250404"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S13.2">
                     <id root="276601a7-9376-4656-b896-a70445e8da73"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2  Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>Repeated-oral and intravenous dosing of tedizolid phosphate in rats in 1 month and 3 month toxicology studies produced dose- and time-dependent bone marrow hypocellularity (myeloid, erythroid, and megakaryocyte), with associated reduction in circulating RBCs, WBCs, and platelets. These effects showed evidence of reversibility and occurred at plasma tedizolid exposure levels (AUC) ≥6-fold greater than the plasma exposure associated with the human therapeutic dose. In a 1-month immunotoxicology study in rats, repeated oral dosing of tedizolid phosphate was shown to significantly reduce splenic B cells and T cells and reduce plasma IgG titers. These effects occurred at plasma tedizolid exposure levels (AUC) ≥3-fold greater than the expected human plasma exposure associated with the therapeutic dose.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="a193a9ca-923e-48f4-af6f-fcab41332f22"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20250404"/>
               <component>
                  <section ID="S14.1">
                     <id root="3c2ae83e-121f-4202-9da5-ffba1e3d9105"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1	Acute Bacterial Skin and Skin Structure Infections </title>
                     <text>
                        <paragraph>
                           <content styleCode="Bold">Adults</content>
                        </paragraph>
                        <paragraph>A total of 1333 adults with acute bacterial skin and skin structure infections (ABSSSI) were randomized in two multicenter, multinational, double-blind, non-inferiority trials.  Both trials compared SIVEXTRO 200 mg once daily for 6 days versus linezolid 600 mg every 12 hours for 10 days.  In Trial 1, patients were treated with oral therapy, while in Trial 2, patients could receive oral therapy after a minimum of one day of intravenous therapy.  Patients with cellulitis/erysipelas, major cutaneous abscess, or wound infection were enrolled in the trials.  Patients with wound infections could have received aztreonam and/or metronidazole as adjunctive therapy for gram-negative bacterial coverage, if needed.  The intent-to-treat (ITT) patient population included all randomized patients.</paragraph>
                        <paragraph>In Trial 1, 332 patients with ABSSSI were randomized to SIVEXTRO and 335 patients were randomized to linezolid.  The majority (91%) of patients treated with SIVEXTRO in Trial 1 were less than 65 years old with a median age of 43 years (range: 18 to 86 years). Patients treated with SIVEXTRO were predominantly male (61%) and White (84%); 13% had BMI ≥35 kg/m<sup>2</sup>, 8% had diabetes mellitus, 35% were current or recent intravenous drug users, and 2% had moderate to severe renal impairment.  The overall median surface area of infection was 188 cm<sup>2</sup>. The types of ABSSSI included were cellulitis/erysipelas (41%), wound infection (29%), and major cutaneous abscess (30%). In addition to local signs and symptoms of infection, patients were also required to have at least one regional or systemic sign of infection at baseline, defined as lymphadenopathy (87% of patients), temperature 38°C or higher (16% of patients), white blood cell count greater than 10,000 cells/mm<sup>3</sup> or less than 4000 cells/mm<sup>3</sup> (42%), or 10% or more band forms on white blood cell differential (4%).</paragraph>
                        <paragraph>The primary endpoint in Trial 1 was early clinical response defined as no increase from baseline lesion area at 48-72 hours after the first dose and oral temperature of ≤37.6°C, confirmed by a second temperature measurement within 24 hours in the ITT population.</paragraph>
                        <paragraph>In Trial 2, 332 patients with ABSSSI were randomized to SIVEXTRO and 334 patients were randomized to linezolid.  The majority (87%) of patients treated with SIVEXTRO in Trial 2 were less than 65 years old with a median age of 46 years (range: 17 to 86 years).  Patients treated with SIVEXTRO were predominantly male (68%) and White (86%); 16% had BMI ≥35 kg/m<sup>2</sup>, 10% had diabetes mellitus, 20% were current or recent intravenous drug users, and 4% had moderate to severe renal impairment.  The overall median surface area of infection was 231 cm<sup>2</sup>. The types of ABSSSI included were cellulitis/erysipelas (50%), wound infection (30%), and major cutaneous abscess (20%). In addition to local signs and symptoms of infection, patients were also required to have at least one regional or systemic sign of infection at baseline, defined as lymphadenopathy (71% of patients), temperature 38°C or higher (31% of patients), white blood cell count greater than 10,000 cells/mm<sup>3</sup> or less than 4000 cells/mm<sup>3</sup> (53%), or 10% or more band forms on white blood cell differential (16%).</paragraph>
                        <paragraph>The primary endpoint in Trial 2 was early clinical response defined as at least a 20% decrease from baseline lesion area at 48-72 hours after the first dose in the ITT population (<linkHtml href="#t10">Table 10</linkHtml>).</paragraph>
                        <table width="100%" ID="t10">
                           <caption>Table 10: Early Clinical Response in the ITT Adult Patient Population</caption>
                           <col width="25%" align="left" valign="top"/>
                           <col width="25%" align="center" valign="top"/>
                           <col width="25%" align="center" valign="top"/>
                           <col width="25%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th/>
                                 <th>SIVEXTRO<br/>(200 mg)</th>
                                 <th>Linezolid<br/>(1200 mg)</th>
                                 <th>Treatment  Difference<br/>(2-sided 95% CI)</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="4">CI=confidence interval</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td colspan="4">
                                    <content styleCode="bold">No increase in lesion surface area from baseline and oral temperature of ≤37.6°C, confirmed by a second temperature measurement within 24 hours at 48-72 hours<footnote>Primary endpoint for Trial 1; sensitivity analysis for Trial 2</footnote>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Trial 1, N</td>
                                 <td>332</td>
                                 <td>335</td>
                                 <td/>
                              </tr>
                              <tr>
                                 <td>  Responder, n (%)</td>
                                 <td>264 (79.5)</td>
                                 <td>266 (79.4)</td>
                                 <td>0.1 (-6.1, 6.2)</td>
                              </tr>
                              <tr>
                                 <td>Trial 2, N</td>
                                 <td>332</td>
                                 <td>334</td>
                                 <td/>
                              </tr>
                              <tr>
                                 <td>  Responder, n (%)</td>
                                 <td>286 (86.1)</td>
                                 <td>281 (84.1)</td>
                                 <td>2.0 (-3.5, 7.3)</td>
                              </tr>
                              <tr>
                                 <td colspan="4">
                                    <content styleCode="bold">At least a 20% decrease from baseline in lesion area at 48-72 hours<footnote>Primary endpoint for Trial 2; sensitivity analysis for Trial 1</footnote>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Trial 1, N</td>
                                 <td>332</td>
                                 <td>335</td>
                                 <td/>
                              </tr>
                              <tr>
                                 <td>  Responder, n (%)</td>
                                 <td>259 (78.0)</td>
                                 <td>255 (76.1)</td>
                                 <td>1.9 (-4.5,  8.3)</td>
                              </tr>
                              <tr>
                                 <td>Trial 2, N</td>
                                 <td>332</td>
                                 <td>334</td>
                                 <td/>
                              </tr>
                              <tr>
                                 <td>  Responder, n (%)</td>
                                 <td>283 (85.2)</td>
                                 <td>276 (82.6)</td>
                                 <td>2.6 (-3.0, 8.2)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>An investigator assessment of clinical response was made at the post-therapy evaluation (PTE) (7 - 14 days after the end of therapy) in the ITT and CE (Clinically Evaluable) populations. Clinical success was defined as resolution or near resolution of most disease-specific signs and symptoms, absence or near resolution of systemic signs of infection if present at baseline (lymphadenopathy, fever, &gt;10% immature neutrophils, abnormal WBC count), and no new signs, symptoms, or complications attributable to the ABSSSI requiring further treatment of the primary lesion (<linkHtml href="#t11">Table 11</linkHtml>).</paragraph>
                        <table width="80%" ID="t11">
                           <caption>Table 11: Investigator-Assessed Clinical Response at Post-therapy Evaluation in ITT and CE Adult Patient Populations from Two Phase 3 ABSSSI Trials</caption>
                           <col align="left" width="15%" valign="top"/>
                           <col align="center" width="30%" valign="top"/>
                           <col align="center" width="25%" valign="top"/>
                           <col align="center" width="30%" valign="top"/>
                           <thead>
                              <tr>
                                 <th/>
                                 <th>SIVEXTRO<br/>(200 mg)<br/>n/N (%)</th>
                                 <th>Linezolid<br/>(1200 mg)<br/>n/N (%)</th>
                                 <th valign="middle">Treatment Difference<br/>(2-sided 95% CI)</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="4">CI=confidence interval; ITT=intent-to-treat; CE=clinically evaluable</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td>Trial 1</td>
                                 <td/>
                                 <td/>
                                 <td/>
                              </tr>
                              <tr>
                                 <td>  ITT</td>
                                 <td>284/332 (85.5)</td>
                                 <td>288/335 (86.0)</td>
                                 <td>-0.5 (-5.8, 4.9)</td>
                              </tr>
                              <tr>
                                 <td>  CE</td>
                                 <td>264/279 (94.6)</td>
                                 <td>267/280 (95.4)</td>
                                 <td>-0.8 (-4.6, 3.0)</td>
                              </tr>
                              <tr>
                                 <td>Trial 2</td>
                                 <td/>
                                 <td/>
                                 <td/>
                              </tr>
                              <tr>
                                 <td>  ITT</td>
                                 <td>292/332 (88.0)</td>
                                 <td>293/334 (87.7)</td>
                                 <td>0.3 (-4.8, 5.3)</td>
                              </tr>
                              <tr>
                                 <td>  CE</td>
                                 <td>268/290 (92.4)</td>
                                 <td>269/280 (96.1)</td>
                                 <td>-3.7 (-7.7, 0.2)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Clinical success by baseline pathogens from the primary infection site or blood cultures for the microbiological intent-to-treat (MITT) patient population for two integrated Phase 3 ABSSSI studies are presented in <linkHtml href="#t12">Table 12</linkHtml> and <linkHtml href="#t13">Table 13</linkHtml>.</paragraph>
                        <table width="100%" ID="t12">
                           <caption>Table 12: Early Clinical Response by Baseline Pathogen from Two Phase 3 ABSSSI Adult Trials (MITT Population)</caption>
                           <col width="32%" align="left" valign="middle"/>
                           <col width="17%" align="center" valign="middle"/>
                           <col width="17%" align="center" valign="middle"/>
                           <col width="17%" align="center" valign="middle"/>
                           <col width="17%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" rowspan="2">Pathogen</th>
                                 <th styleCode="Rrule Botrule" colspan="2">No increase in lesion surface area from baseline and oral temperature of ≤37.6°C<footnote>Primary endpoint of Trial 1</footnote>
                                 </th>
                                 <th styleCode="Rrule Botrule" colspan="2">At least a 20% decrease from baseline in lesion  area<footnote>Primary endpoint of Trial 2</footnote>
                                 </th>
                              </tr>
                              <tr styleCode="Botrule">
                                 <th align="center" styleCode="Rrule">SIVEXTRO<br/>(200 mg)<br/>n/N (%)</th>
                                 <th styleCode="Rrule">Linezolid<br/>(1200 mg)<br/>n/N (%)</th>
                                 <th styleCode="Rrule">SIVEXTRO<br/>(200 mg)<br/>n/N (%)</th>
                                 <th styleCode="Rrule">Linezolid<br/>(1200 mg)<br/>n/N (%)</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="5">Pooled analysis; n=number of patients in the specific category; N=Number of patients with the specific pathogen isolated from the ABSSSI</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Staphylococcus aureus</content>
                                 </td>
                                 <td styleCode="Rrule">276/329 (83.9)</td>
                                 <td styleCode="Rrule">278/342 (81.3)</td>
                                 <td styleCode="Rrule">280/329 (85.1)</td>
                                 <td styleCode="Rrule">276/342 (80.7)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Methicillin-resistant<content styleCode="italics"> S. aureus</content>
                                 </td>
                                 <td styleCode="Rrule">112/141 (79.4)</td>
                                 <td styleCode="Rrule">113/146 (77.4)</td>
                                 <td styleCode="Rrule">114/141 (80.9)</td>
                                 <td styleCode="Rrule">111/146 (76.0)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Methicillin-susceptible<content styleCode="italics"> S. aureus</content>
                                 </td>
                                 <td styleCode="Rrule">164/188 (87.2)</td>
                                 <td styleCode="Rrule">167/198 (84.3)</td>
                                 <td styleCode="Rrule">166/188 (88.3)</td>
                                 <td styleCode="Rrule">167/198 (84.3)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Streptococcus pyogenes </content>
                                 </td>
                                 <td styleCode="Rrule">27/33 (81.8)</td>
                                 <td styleCode="Rrule">18/20 (90.0)</td>
                                 <td styleCode="Rrule">25/33 (75.8)</td>
                                 <td styleCode="Rrule">16/20 (80.0)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Streptococcus anginosus </content>Group</td>
                                 <td styleCode="Rrule">22/30 (73.3)</td>
                                 <td styleCode="Rrule">26/28 (92.9)</td>
                                 <td styleCode="Rrule">22/30 (73.3)</td>
                                 <td styleCode="Rrule">25/28 (89.3)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Streptococcus agalactiae</content>
                                 </td>
                                 <td styleCode="Rrule">6/9 (66.7)</td>
                                 <td styleCode="Rrule">8/10 (80.0)</td>
                                 <td styleCode="Rrule">6/9 (66.7)</td>
                                 <td styleCode="Rrule">7/10 (70.0)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Enterococcus faecalis</content>
                                 </td>
                                 <td styleCode="Rrule">7/10 (70.0)</td>
                                 <td styleCode="Rrule">3/4 (75.0)</td>
                                 <td styleCode="Rrule">6/10 (60.0)</td>
                                 <td styleCode="Rrule">1/4 (25.0)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Baseline bacteremia in the tedizolid arm with relevant pathogens included two subjects with MRSA, four subjects with MSSA, two subjects with <content styleCode="italics">S. pyogenes</content>, one subject with <content styleCode="italics">S. </content>
                           <content styleCode="italics">agalactiae</content>, and one subject with <content styleCode="italics">S. constellatus.  </content>All of these subjects were Responders at the 48-72 hour evaluation.  At the Post-therapy Evaluation (PTE), 8 of 10 subjects were considered clinical successes.</paragraph>
                        <table width="80%" ID="t13">
                           <caption>Table 13: Clinical Response at PTE by Baseline Pathogen from Two Phase 3 ABSSSI Adult Trials (MITT Population)</caption>
                           <col width="44%" align="left" valign="middle"/>
                           <col width="28%" align="center" valign="middle"/>
                           <col width="28%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" rowspan="2">Pathogen</th>
                                 <th styleCode="Rrule Botrule" colspan="2">Clinical Response at PTE</th>
                              </tr>
                              <tr styleCode="Botrule">
                                 <th align="center" styleCode="Rrule">SIVEXTRO<br/>(200 mg)<br/>n/N (%)</th>
                                 <th styleCode="Rrule">Linezolid<br/>(1200 mg)<br/>n/N (%)</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3">Pooled analysis; n=number of patients in the specific category; N=Number of patients with the specific pathogen isolated from the ABSSSI</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Staphylococcus aureus</content>
                                 </td>
                                 <td styleCode="Rrule">291/329 (88.5)</td>
                                 <td styleCode="Rrule">303/342 (88.6)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Methicillin-resistant<content styleCode="italics"> S. aureus</content>
                                 </td>
                                 <td styleCode="Rrule">118/141 (83.7)</td>
                                 <td styleCode="Rrule">119/146 (81.5)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Methicillin-susceptible<content styleCode="italics"> S. aureus</content>
                                 </td>
                                 <td styleCode="Rrule">173/188 (92.0)</td>
                                 <td styleCode="Rrule">186/198 (93.9)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Streptococcus pyogenes </content>
                                 </td>
                                 <td styleCode="Rrule">30/33 (90.9)</td>
                                 <td styleCode="Rrule">19/20 (95.0)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Streptococcus anginosus </content>Group</td>
                                 <td styleCode="Rrule">21/30 (70.0)</td>
                                 <td styleCode="Rrule">25/28 (89.3)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Streptococcus agalactiae</content>
                                 </td>
                                 <td styleCode="Rrule">8/9 (88.9)</td>
                                 <td styleCode="Rrule">8/10 (80.0)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Enterococcus faecalis</content>
                                 </td>
                                 <td styleCode="Rrule">7/10 (70.0)</td>
                                 <td styleCode="Rrule">4/4 (100.0)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Baseline bacteremia in the tedizolid arm with relevant pathogens included two subjects with MRSA, four subjects with MSSA, two subjects with <content styleCode="italics">S. pyogenes</content>, one subject with <content styleCode="italics">S. </content>
                           <content styleCode="italics">agalactiae</content>, and one subject with <content styleCode="italics">S. constellatus.  </content>All of these subjects were Responders at the 48-72 hour evaluation. At the Post-therapy Evaluation (PTE) 8 of 10 subjects were considered clinical successes.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Pediatric Patients</content>
                        </paragraph>
                        <paragraph>The safety and efficacy of SIVEXTRO were investigated in Pediatric Trials 1 and 2. Pediatric Trial 1 included pediatric patients 12 to &lt; 18 years of age who were investigated in a randomized, single blind, active-controlled trial of 120 patients with clinically documented ABSSSI (91 receiving tedizolid, 29 receiving comparator). Patients were randomized in a 3:1 ratio with stratification by geographic region to receive SIVEXTRO IV and/or oral therapy, dosed 200 mg once daily for 6 days, or comparator IV and/or oral therapy, dosed over 10 days. Comparator therapy was selected by the investigator from a list of 5 IV and 4 oral comparators per local standard of care. The most frequently used comparators were cefazolin (11 patients) and vancomycin (8 patients).</paragraph>
                        <paragraph>Additionally, Pediatric Trial 2 (NCT03176134) evaluated the safety and efficacy of SIVEXTRO in pediatric patients 4 months to &lt;12 years of age in a randomized, single blind, active-controlled trial of 100 patients with clinically documented ABSSSI (75 receiving tedizolid, 25 receiving comparator). Patients were randomized in a 3:1 ratio to receive SIVEXTRO for 6 to 10 days or comparator for 10 to 14 days. SIVEXTRO (IV and/or oral) was dosed as a weight-based dose of 2 to 2.5 mg/kg every 12 hours or as 200 mg given once daily. Patients who received oral therapy received an oral suspension formulation that is not currently approved for use. Comparator therapy was selected from a pre-specified list by the investigator and dosed per local standard of care.</paragraph>
                        <paragraph>The primary objective of Pediatric Trials 1 and 2 was to evaluate the safety and tolerability of SIVEXTRO. The trials were not powered for comparative inferential efficacy analysis. Clinical response at the test of cure visit (Day 18-25) was assessed by a blinded investigator in the ITT population (all randomized patients). Clinical successes were required to have resolution or near resolution of all related signs and symptoms such that no further antibacterial therapy was needed. Early clinical response, defined as at least a 20% reduction in lesion size at 48-72 hours after start of treatment, was also assessed in the ITT population.</paragraph>
                        <paragraph>In Pediatric Trial 1, clinical success at test of cure was 96.7% (88/91) in the tedizolid group and 93.1% (27/29) in the comparator group (difference: 3.6%, 95% CI: -6.3, 13.5). Early clinical response at 48-72 hours was 92.3% (84/91) in the tedizolid group and 96.6% (28/29) in the comparator group (difference: -4.2%, 95% CI: -12.9, 4.4).</paragraph>
                        <paragraph>In Pediatric Trial 2, clinical success at test of cure was 93.3% (70/75) in the tedizolid group and 92.0% (23/25) in the comparator group (difference: 1.3%, 95% CI: -10.7, 13.4). Early clinical response was not adequately assessed in Pediatric Trial 2 because an in-person outpatient visit at this timepoint was not required during the COVID-19 pandemic.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="e86e8ce0-0c34-4269-9303-1390d0d74158"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20250404"/>
               <component>
                  <section ID="S16.1">
                     <id root="987b67ad-0f8a-4b22-8885-fb2aff1f0696"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>16.1 Tablets</title>
                     <text>
                        <paragraph>SIVEXTRO Tablets are yellow film-coated oval tablets containing 200 mg of tedizolid phosphate; each tablet is debossed with "TZD" on one side and "200" on the other side. </paragraph>
                        <paragraph>They are supplied as follows:</paragraph>
                        <paragraph>HDPE bottles of 30 tablets with child-resistant closure (NDC 67919-041-04)</paragraph>
                        <paragraph>Unit dose blister packs of 6 tablets (NDC 67919-041-05)</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section ID="S16.2">
                     <id root="d30340b8-a9b1-4819-85c3-d3cf2d89cab2"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>16.2 For Injection</title>
                     <text>
                        <paragraph>SIVEXTRO is supplied as a sterile, white to off-white lyophilized powder for injection in single-dose vials of 200 mg. Each 200 mg vial must be reconstituted with Sterile Water for Injection and subsequently diluted with 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP.</paragraph>
                        <paragraph>They are supplied as follows:</paragraph>
                        <paragraph>Package of ten 200 mg single-dose vials (NDC 67919-040-02)</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section ID="S16.3">
                     <id root="c12509f5-4add-4c34-a185-3161ed99cba6"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>16.3	Storage and Handling</title>
                     <text>
                        <paragraph>SIVEXTRO Tablets and SIVEXTRO for Injection should be stored at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Discard any unused portion of the single-dose vials.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="c6cc2fac-ed1c-4203-b8f5-6289b3dc03e4"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information).</paragraph>
               </text>
               <effectiveTime value="20250404"/>
               <component>
                  <section>
                     <id root="58ced381-1dec-4b36-b5a5-9b5806f85637"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Administration with Food</content>
                        </paragraph>
                        <paragraph>Patients should be informed that SIVEXTRO Tablets may be taken with or without food and without any dietary restrictions <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2</linkHtml>, <linkHtml href="#S2.3">2.3)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="da14acd7-5dac-40ad-841b-ea36417be9df"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Antibacterial Resistance</content>
                        </paragraph>
                        <paragraph>Patients should be counseled that antibacterial drugs including SIVEXTRO should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When SIVEXTRO is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by SIVEXTRO or other antibacterial drugs in the future <content styleCode="italics">[see <linkHtml href="#S1.2">Indications and Usage (1.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Missed Doses</content>
                        </paragraph>
                        <paragraph>Patients should be informed that if they miss a SIVEXTRO oral dose, they should take the dose as soon as possible anytime up to 8 hours prior to their next scheduled dose. If less than 8 hours remains before the next dose, then they should wait until their next scheduled dose. Patients should take the prescribed number of doses <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2</linkHtml>, <linkHtml href="#S2.3">2.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="b7a82e3a-dab8-4fcc-b87b-c8d0b15a7a86"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Potentially Serious Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Patients should be advised that diarrhea is a common problem caused by antibacterial drugs including SIVEXTRO and usually resolves when the drug is discontinued.  Sometimes after starting treatment with antibacterial drugs, patients can develop frequent watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibacterial drug and may be a sign of a more serious intestinal infection <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml> and </content>
                           <content styleCode="italics">
                              <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>.  If this occurs, patients should contact their healthcare provider as soon as possible.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="6a1ef22d-08db-45f7-8983-a1ebc17d54b4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Embryo-Fetal Toxicity</content>
                        </paragraph>
                        <paragraph>Based on animal data, advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="7d51a1b1-1c5c-41eb-a65e-60058c2c6d24"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manuf. for: Merck Sharp &amp; Dohme LLC <br/>
                     Rahway, NJ 07065, USA</paragraph>
                  <paragraph>Sivextro Tablets<br/>Manufactured by: Patheon Inc.<br/>Whitby, Ontario, L1N 5Z5 Canada</paragraph>
                  <paragraph>Sivextro for Injection<br/>Manufactured by: Patheon Italia S.p.A.<br/>03013, Ferentino, FR Italy</paragraph>
                  <paragraph>For patent information: <content styleCode="underline">
                        <linkHtml href="www.msd.com/research/patent">www.msd.com/research/patent</linkHtml>
                     </content>
                  </paragraph>
                  <paragraph>Copyright © 2015-2025 Merck &amp; Co., Inc., Rahway, NJ, USA, and its affiliates.
                     <br/>All rights reserved.</paragraph>
                  <paragraph>uspi-mk1986-mf-2504r012</paragraph>
               </text>
               <effectiveTime value="20250404"/>
            </section>
         </component>
         <component>
            <section>
               <id root="ec721f95-5f66-4358-8035-d402c637f9c0"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%">
                     <col width="100%" align="center" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule">
                              <content styleCode="bold">Patient Information<br/>SIVEXTRO<sup>®</sup>
                              </content>(sih-vex-tro)<br/>(tedizolid phosphate)<br/>tablets</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">What you need to know about SIVEXTRO</content>
                  </paragraph>
                  <table width="100%">
                     <col width="100%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule">
                              <list listType="unordered" styleCode="disc">
                                 <item>Before you take this medicine, be sure you understand what it is for and how to take it safely.</item>
                                 <item>Keep this information. </item>
                                 <item>If you have questions about this medicine, ask your doctor or pharmacist.</item>
                                 <item>Every time you get a refill, look at the Patient Information sheet that comes with it. There may be new information.</item>
                                 <item>Remember that your doctor has prescribed this medicine only for you. Never give it to anyone else.</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule">
                              <content styleCode="bold">What is SIVEXTRO?</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>SIVEXTRO tablet is for adults and for children weighing at least 77 pounds (35 kg) who have a skin infection or an infection in the tissue below the skin. SIVEXTRO is an antibiotic that works by stopping the growth of certain bacteria.</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule">
                              <content styleCode="bold">What should I tell my doctor before taking SIVEXTRO?</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Medical Conditions</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Tell your doctor if you:</content>
                  </paragraph>
                  <list>
                     <item>have diarrhea or have ever had diarrhea while taking antibiotics. Tell your doctor, even if you had diarrhea that occurred up to 2 months after you took the antibiotic.</item>
                     <item>are allergic to tedizolid phosphate or any of the ingredients in SIVEXTRO. See the end of this Patient Information for a complete list of ingredients in SIVEXTRO.</item>
                     <item>are pregnant or plan to get pregnant, tell your doctor if you become pregnant while taking SIVEXTRO. It is not known if SIVEXTRO will harm your baby while you are pregnant. You and your doctor should decide together if you will take SIVEXTRO.</item>
                     <item>are breastfeeding or plan to breastfeed, tell your doctor before you take SIVEXTRO. It is not known if SIVEXTRO passes into your breast milk. You and your doctor should decide together if you will take SIVEXTRO or breastfeed.</item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule">
                              <content styleCode="bold">Are you taking other medicines?</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <list listType="unordered" styleCode="square">
                     <item>SIVEXTRO can affect the way other medicines work, and other medicines can affect how SIVEXTRO works. Some medicines cannot be taken with SIVEXTRO at all. Your doctor will tell you if it is safe to take SIVEXTRO with other medicines.</item>
                     <item>It is especially important to tell your doctor if you take any of the following medicines:<list listType="unordered" styleCode="circle">
                           <item>Methotrexate (for cancer or rheumatoid arthritis)</item>
                           <item>Topotecan (for cancer)</item>
                           <item>Rosuvastatin (for cholesterol) </item>
                        </list>
                     </item>
                     <item>
                        <content styleCode="bold">Tell your doctor about all of the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal and dietary supplements.</item>
                     <item>Know the medicines you take. Keep a list of them and show the list to your doctor and pharmacist when you get a new medicine.</item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule">
                              <content styleCode="bold">How do I take SIVEXTRO?</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <list listType="unordered" styleCode="square">
                     <item>
                        <content styleCode="bold">Do not</content> give SIVEXTRO tablets to children weighing less than 77 pounds (35 kg).
                     </item>
                     <item>Take SIVEXTRO exactly how your doctor tells you to take it.</item>
                     <item>
                        <content styleCode="bold">Take 1 SIVEXTRO tablet 1 time each day.</content>
                     </item>
                     <item>
                        <content styleCode="bold">Take SIVEXTRO for 6 days, at the same time every day</content>.</item>
                     <item>Take SIVEXTRO by mouth, with or without food.</item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule">
                              <content styleCode="bold">What if I forget to take SIVEXTRO?</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <list listType="unordered" styleCode="square">
                     <item>If you miss a dose, take the missed dose as soon as you remember.<br/>If it is less than 8 hours until your next dose, skip the missed dose and take the next tablet at the time you usually take it.</item>
                     <item>Do not take 2 doses of SIVEXTRO at the same time to make up for a missed dose. </item>
                     <item>If you are not sure how to take SIVEXTRO, call your doctor or pharmacist.</item>
                     <item>Take all 6 tablets to finish your SIVEXTRO, even if you have missed a dose. </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">If you do not finish your medicine, SIVEXTRO may not work.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">You may get sick again and the remaining bacteria may be harder to treat.</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule">
                              <content styleCode="bold">What are the possible side effects of SIVEXTRO?</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>SIVEXTRO may cause serious side effects, including diarrhea from <content styleCode="bold">C-diff (Clostridioides difficile) infection.</content> Call your healthcare provider right away if you get stomach cramps, fever, watery diarrhea, diarrhea that does not go away, or bloody stools. C-diff infection can happen 2 or more months after you have finished your antibacterial medicine.</paragraph>
                  <paragraph>C-diff is an infection of your intestines (bowels) that can happen with many antibiotics like SIVEXTRO and may cause mild diarrhea to life-threatening swelling of your intestines (colitis).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Common side effects of SIVEXTRO include:</content>
                  </paragraph>
                  <table width="50%" styleCode="Noautorules">
                     <col width="4%" align="left" valign="top"/>
                     <col width="48%" align="left" valign="top"/>
                     <col width="48%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td/>
                           <td>
                              <list listType="unordered" styleCode="square">
                                 <item>nausea</item>
                                 <item>headache</item>
                                 <item>dizziness</item>
                                 <item>vomiting</item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="square">
                                 <item>diarrhea </item>
                                 <item>increased liver enzymes</item>
                                 <item>painful swelling or inflammation of veins (phlebitis)</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Some less common side effects are:</content>
                  </paragraph>
                  <paragraph>Problems with your skin</paragraph>
                  <list listType="unordered" styleCode="square">
                     <item>itching, red or itchy rash, hives, acne </item>
                     <item>hot flushes or feeling like you are blushing or your face, neck or chest is red</item>
                     <item>not able to feel something as well</item>
                     <item>a tingling or prickling sensation </item>
                  </list>
                  <paragraph>Problems with your sleep</paragraph>
                  <list listType="unordered" styleCode="square">
                     <item>hard time sleeping</item>
                  </list>
                  <paragraph>Problems with your body</paragraph>
                  <list listType="unordered" styleCode="square">
                     <item>numbness </item>
                     <item>facial paralysis </item>
                  </list>
                  <paragraph>Problems with infections</paragraph>
                  <list listType="unordered" styleCode="square">
                     <item>vagina that is infected, inflamed, or itchy </item>
                     <item>fungal infections of skin, mouth </item>
                  </list>
                  <paragraph>Problems with your eyes</paragraph>
                  <list listType="unordered" styleCode="square">
                     <item>eye strain</item>
                     <item>blurred or impaired vision</item>
                     <item>seeing dots or spots in your eyes</item>
                  </list>
                  <paragraph>Problems with your heart</paragraph>
                  <list listType="unordered" styleCode="square">
                     <item>Your heartbeat does not feel normal. It could feel like your heart is beating too fast or pumping harder than usual.</item>
                  </list>
                  <paragraph>Problems with your vascular system</paragraph>
                  <list listType="unordered" styleCode="square">
                     <item>high blood pressure</item>
                  </list>
                  <paragraph>Problems with your blood work</paragraph>
                  <paragraph>Your doctor may tell you that you have the following while taking SIVEXTRO:</paragraph>
                  <list listType="unordered" styleCode="square">
                     <item>a low white blood cell count</item>
                     <item>anemia (low red blood cells)</item>
                     <item>low platelet count, the small cells involved in clotting your blood</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Side effects where the frequency is not known:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="square">
                     <item>bleeding or bruising easily</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">If you have any side effect that bothers you or does not go away, tell your doctor.</content>
                  </paragraph>
                  <paragraph>These are not all the possible side effects of SIVEXTRO. For information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule">
                              <content styleCode="bold">How should I store SIVEXTRO?</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <list listType="unordered" styleCode="square">
                     <item>Store SIVEXTRO at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                     <item>Keep SIVEXTRO and all medicines out of the reach of children.</item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule">
                              <content styleCode="bold">General information about SIVEXTRO.</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <list listType="unordered" styleCode="disc">
                     <item>Medicines are sometimes prescribed for purposes that are not mentioned here. </item>
                     <item>Do not use SIVEXTRO for a condition for which it was not prescribed.</item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule">
                              <content styleCode="bold">What if I have questions?</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <list listType="unordered" styleCode="square">
                     <item>Call your doctor.</item>
                     <item>Call the company that makes SIVEXTRO at 1-800-444-2080.</item>
                     <item>Go to the website – www.SIVEXTRO.com. </item>
                     <item>You can ask your doctor or pharmacist for information about SIVEXTRO that is written for health professionals.</item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule">
                              <content styleCode="bold">What are the ingredients in SIVEXTRO?</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <list listType="unordered" styleCode="square">
                     <item>The active ingredient: tedizolid phosphate.</item>
                     <item>The inactive ingredients: crospovidone, magnesium stearate, mannitol, microcrystalline cellulose, and povidone. Film coating: polyethylene glycol/macrogol, polyvinyl alcohol, talc, titanium dioxide, and yellow iron oxide.</item>
                  </list>
                  <paragraph>Manuf. for: Merck Sharp &amp; Dohme LLC <br/>
                     Rahway, NJ 07065, USA</paragraph>
                  <paragraph>Sivextro tablets Manufactured by: Patheon Inc., Whitby, Ontario, L1N 5Z5 Canada</paragraph>
                  <paragraph>Sivextro for injection Manufactured by: Patheon Italia S.p.A., 03013, Ferentino, FR Italy</paragraph>
                  <paragraph>For patent information: <content styleCode="underline">
                        <linkHtml href="www.msd.com/research/patent">www.msd.com/research/patent. </linkHtml>
                     </content>The trademarks depicted herein are owned by their respective companies.</paragraph>
                  <paragraph>Copyright © 2017-2025 Merck &amp; Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved.  </paragraph>
                  <paragraph>usppi-mk1986-mf-2504r005</paragraph>
                  <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration                Revised: 4/2025</paragraph>
               </text>
               <effectiveTime value="20250404"/>
            </section>
         </component>
         <component>
            <section>
               <id root="d83cbe4c-b432-44a5-a7bf-57f6103437bf"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 200 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 67919-041-04<br/>30 tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold italics">Sivextro</content>
                     <sup>®</sup>
                     <br/>
                     <content styleCode="bold">(tedizolid phosphate) tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">200 mg per tablet</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
               </text>
               <effectiveTime value="20250404"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>Principal Display Panel - 200 mg Tablet Bottle Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="sivextro-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="936b34d1-e81e-400e-a660-21eb097faa0c"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 200 mg Tablet Blister Pack Carton</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 67919-041-05<br/>6 tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold italics">Sivextro</content>
                     <sup>®</sup>
                     <br/>
                     <content styleCode="bold">(tedizolid phosphate) tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">200 mg per tablet</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20250404"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>Principal Display Panel - 200 mg Tablet Blister Pack Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="sivextro-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="108a78a0-ba20-4e58-9668-3dcc9bd28319"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 200 mg Vial Carton</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 67919-040-02<br/>10 single-dose vials</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold italics">Sivextro</content>
                     <sup>®</sup>
                     <br/>
                     <content styleCode="bold">(tedizolid phosphate) for injection</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">200 mg per vial <br/>For Intravenous Infusion</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Must be reconstituted and further<br/>diluted prior to administration<br/>by intravenous infusion.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Sterile<br/>Rx only </content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20250404"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>Principal Display Panel - 200 mg Vial Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="sivextro-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>